JP2023171784A - Topical skin composition - Google Patents

Abstract

To provide a topical skin composition having inhibited precipitation.SOLUTION: A topical skin composition containing (A) 3 mass% or more of nicotinic-acid amide, (B) a preservative, and (C) an organic acid, organic acid salt, or amphipathic compound is prepared.SELECTED DRAWING: None

Description

The present invention relates to compositions for external use on the skin. More particularly, the present invention relates to external skin compositions containing nicotinamide.

Nicotinamide is a type of vitamin that has been used in the skin care field to promote blood circulation, anti-inflammation, and promote ceramide synthesis. It is also known to have beneficial effects.

For example, Patent Document 1 proposes a whitening agent containing as an active ingredient one or more selected from the group consisting of riboflavin, pyridoxine hydrochloride, nicotinamide, and calcium pantothenate.

Further, in Patent Document 2, it is characterized by containing (a) nicotinic acid amide and (b) one or more types selected from the group consisting of urea and α-hydroxycarboxylic acid compounds having 2 to 28 carbon atoms. Cosmetics that prevent skin aging have been proposed.

JP2004-217629A Japanese Patent Application Publication No. 10-130135

Cosmetics and the like generally contain preservatives along with active ingredients and the like. The present inventors have found a novel problem in that, especially when an organic acid or an amphiphilic component is blended into a preservative, precipitation occurs, which does not occur with each component alone.

An object of the present invention is to provide a composition for external use on the skin in which precipitation is suppressed even when the composition contains a preservative and an organic acid or an amphiphilic component.

As a result of intensive studies to solve the above problems, the present inventors discovered that precipitation caused by the combination of a preservative and an organic acid or an amphiphilic component can be suppressed by adding nicotinic acid amide. I was able to complete it.

（式中、
Ｚは、水素原子、又は、炭素数１～３０のヒドロキシ化合物からｎ個のヒドロキシ基を
除去することによって得られる残基を意味し；
ＡＯは、３～４個の炭素原子を有するオキシアルキレン基を意味し；
ＥＯは、オキシエチレン基を意味し；
ＢＯは、４個の炭素原子を有するオキシアルキレン基を意味し；
ｎは、１～９を意味し；
ａ，ｂ及びｃは、それぞれＡＯ、ＥＯ、ＢＯの平均付加モル数を意味し、独立して０～
２００である。但し、ａ、ｂ及びｃが全て０になることはない。また、ｎが２以上の時、
複数のａ、ｂ及びｃはそれぞれ同一でも異なってもよい。Ｚが水素原子の時は、ｎは１で
ある。
なお、ＡＯ及びＥＯは、ランダムに又はブロックの形態で付加されていてよい。）
項４.
前記（Ｃ）成分が、下記一般式（ＩＩ）で表される化合物、２－メタクリロイルオキシ
エチルホスホリルコリン・メタクリル酸ブチル共重合体、（エイコサン二酸／テトラデカ
ン二酸）デカグリセリル、シクロヘキサンジカルボン酸ビスエトキシジグリコール、コハ
ク酸ジエチルヘキシル、コハク酸ジエトキシエチル、及び、炭素数５～１０のアルカンジ
オールからなる群より選ばれる１種又は２種以上である、項１～３のいずれか１項に記載
の皮膚外用組成物：

（式中、
Ｚは、水素原子、又は、炭素数１～３０のヒドロキシ化合物からｎ個のヒドロキシ基を
除去することによって得られる残基を意味し；
ＡＯは、３～４個の炭素原子を有するオキシアルキレン基を意味し；
ＥＯは、オキシエチレン基を意味し；
ｎは、１～９を意味し；
ａ及びｂは、それぞれＡＯ、ＥＯの平均付加モル数を意味し、独立して０～２００であ
る。但し、ａ及びｂが全て０になることはない。また、ｎが２以上の時、複数のａ、ｂは
それぞれ同一でも異なってもよい。Ｚが水素原子の時はｎは１である。
なお、ＡＯ及びＥＯは、ランダムに又はブロックの形態で付加されていてよい。）
項５.
前記一般式（Ｉ）及び（ＩＩ）において、Ｚが、水素原子であるか、若しくは、炭素数
４～２４のアルキルモノアルコール、グリセリン、トリメチロールプロパン、エリスリト
ール、ペンタエリスリトール、炭素数１～２４のアルキルグルコシド、ジグリセリン、キ
シリトール、ジペンタエリスリトール、ソルビトール、イノシトール、スクロース、トレ
ハロース、又は、マルチトールからｎ個のヒドロキシ基を除去することによって得られる
残基である、項３又は４に記載の皮膚外用組成物。
項６.
前記一般式（Ｉ）及び（ＩＩ）において、Ｚが、水素原子であるか、若しくは、炭素数
４～２４のアルキルモノアルコール、グリセリン、炭素数１～２４のアルキルグルコシド
、又は、ジグリセリンからｎ個のヒドロキシ基を除去することによって得られる残基であ
る、項３又は４に記載の皮膚外用組成物。
項７.
前記（Ｂ）成分が、パラオキシ安息香酸エステル、安息香酸、安息香酸塩、デヒドロ酢
酸、デヒドロ酢酸塩、チモール、イソプロピルメチルフェノール、カプリルヒドロキサム
酸、ブチルカルバミン酸ヨウ化プロピニル、ブチルカルバミン酸ヨウ化プロピニルの塩、
ブチルカルバミン酸ヨウ化プロピニル誘導体、ソルビン酸、ソルビン酸塩、クロロブタノ
ール、及びメチルイソチアゾリンからなる群より選択される少なくとも１種である、項１
～６のいずれか１項に記載の皮膚外用組成物。
項８．
さらに、紫外線吸収剤を含有する、項１～７のいずれか１項記載の皮膚外用組成物。
項９．
前記紫外線吸収剤の総含有量が２０質量％以下である、項８記載の皮膚外用組成物。
項１０．
さらに、紫外線防御剤を含有する、項１～９のいずれか１項記載の皮膚外用組成物。
項１１．
前記紫外線吸収剤がサリチル酸系紫外線吸収剤、ケイ皮酸系紫外線吸収剤、ベンゾイル
メタン系紫外線吸収剤、安息香酸エステル誘導体紫外線吸収剤、トリアジン誘導体紫外線
吸収剤、ベンザルマロナート誘導体紫外線吸収剤、オクトクリレン系紫外線吸収剤、イミ
ダゾ-ルスルホン酸誘導体紫外線吸収剤、及びベンゾフェノン誘導体紫外線吸収剤からな
る群より選択される１種以上である、項１～１０のいずれか１項記載の皮膚外用組成物。
項１２．
前記紫外線吸収剤がパラメトキシケイ皮酸２－エチルヘキシル、４－ｔｅｒｔ－ブチル
－４’－メトキシジベンゾイルメタン、２－［４－（ジエチルアミノ）－２－ヒドロキシ
ベンゾイル］安息香酸ヘキシルエステル、２，４－ビス－［｛４－（２－エチルヘキシル
オキシ）－２－ヒドロキシ｝－フェニル］－６－（４－メトキシフェニル）－１，３，５
－トリアジン、２，４，６－トリス［４－（２－エチルヘキシルオキシカルボニル）アニ
リノ］－１，３，５－トリアジン、２－フェニルベンゾイミダゾ－ル－５－スルホン酸か
らなる群より選択される１種以上である、項１～１１のいずれか１項記載の皮膚外用組成
物。
項１３．
さらに、美白成分を０．００１～１０質量％含有する、項１～１２のいずれか１項記載
の皮膚外用組成物。
項１４．
さらに、抗炎症成分を０．００１～５質量％含有する、項１～１３のいずれか１項記載
の皮膚外用組成物。
項１５．
さらに、酸性ムコ多糖類を含有する、項１～１４のいずれか１項記載の皮膚外用組成物
。
項１６．
さらに、油分、界面活性剤、及び増粘剤からなる群より選択される１種又は２種以上を
含有する、項１～１５のいずれか１項記載の皮膚外用組成物。 That is, the present invention provides the following composition for external use on the skin.
Item 1.
(A) 3% by mass or more of nicotinic acid amide;
A composition for external use on the skin, comprising (B) a preservative; and (C) at least one member selected from the group consisting of organic acids, organic acid salts, derivatives of organic acids, and amphipathic compounds.
Section 2.
The component (C) is
Tranexamic acid or its salts, lactic acid or its salts, citric acid or its salts, succinic acid or its salts, salicylic acid or its salts, gluconic acid or its salts, phytic acid or its salts, tartaric acid or its salts, ascorbic acid phosphate ester Item 1, which is at least one selected from the group consisting of sodium, magnesium ascorbic acid phosphate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, and ascorbic acid-2-glucoside. Composition for external use on the skin.
Section 3.
The component (C) is one or two selected from the group consisting of a compound represented by the following general formula (I), a phosphorylcholine-containing polymer, a divalent carboxylic acid ester, and an alkanediol having 5 to 10 carbon atoms. The skin external composition according to item 1 or 2, which is as follows:

(In the formula,
Z means a hydrogen atom or a residue obtained by removing n hydroxy groups from a hydroxy compound having 1 to 30 carbon atoms;
AO means an oxyalkylene group having 3 to 4 carbon atoms;
EO means oxyethylene group;
BO means an oxyalkylene group having 4 carbon atoms;
n means 1 to 9;
a, b and c mean the average number of added moles of AO, EO, and BO, respectively, and independently range from 0 to
It is 200. However, a, b, and c will not all be 0. Also, when n is 2 or more,
A plurality of a, b and c may be the same or different. When Z is a hydrogen atom, n is 1.
Note that AO and EO may be added randomly or in the form of blocks. )
Section 4.
The component (C) is a compound represented by the following general formula (II), 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer, decaglyceryl (eicosanedioic acid/tetradecanedioic acid), bisethoxy cyclohexanedicarboxylate According to any one of Items 1 to 3, the compound is one or more selected from the group consisting of diglycol, diethylhexyl succinate, diethoxyethyl succinate, and alkanediol having 5 to 10 carbon atoms. Composition for external use on the skin:

(In the formula,
Z means a hydrogen atom or a residue obtained by removing n hydroxy groups from a hydroxy compound having 1 to 30 carbon atoms;
AO means an oxyalkylene group having 3 to 4 carbon atoms;
EO means oxyethylene group;
n means 1 to 9;
a and b mean the average number of added moles of AO and EO, respectively, and independently range from 0 to 200. However, a and b are never all 0. Further, when n is 2 or more, the plurality of a's and b's may be the same or different. When Z is a hydrogen atom, n is 1.
Note that AO and EO may be added randomly or in the form of blocks. )
Section 5.
In the general formulas (I) and (II), Z is a hydrogen atom, or an alkyl monoalcohol having 4 to 24 carbon atoms, glycerin, trimethylolpropane, erythritol, pentaerythritol, or an alkyl monoalcohol having 4 to 24 carbon atoms. The skin according to item 3 or 4, which is a residue obtained by removing n hydroxy groups from alkyl glucoside, diglycerin, xylitol, dipentaerythritol, sorbitol, inositol, sucrose, trehalose, or maltitol. External composition.
Section 6.
In the general formulas (I) and (II), Z is a hydrogen atom, or an alkyl monoalcohol having 4 to 24 carbon atoms, glycerin, an alkyl glucoside having 1 to 24 carbon atoms, or diglycerin to n Item 5. The skin external composition according to Item 3 or 4, which is a residue obtained by removing a hydroxy group.
Section 7.
The component (B) is paraoxybenzoic acid ester, benzoic acid, benzoate, dehydroacetic acid, dehydroacetate, thymol, isopropylmethylphenol, caprylic hydroxamic acid, propynyl butylcarbamate iodide, propynyl butylcarbamate iodide. salt,
Item 1: at least one member selected from the group consisting of butylcarbamic acid propynyl iodide derivative, sorbic acid, sorbate, chlorobutanol, and methylisothiazoline.
The skin external composition according to any one of items 1 to 6.
Section 8.
Item 8. The skin external composition according to any one of Items 1 to 7, further comprising an ultraviolet absorber.
Item 9.
Item 9. The skin external composition according to Item 8, wherein the total content of the ultraviolet absorber is 20% by mass or less.
Item 10.
Item 10. The skin external composition according to any one of Items 1 to 9, further comprising a UV protection agent.
Item 11.
The UV absorbers include salicylic acid UV absorbers, cinnamic acid UV absorbers, benzoylmethane UV absorbers, benzoate derivative UV absorbers, triazine derivative UV absorbers, benzalmalonate derivative UV absorbers, and octocrylene. Item 11. The skin external composition according to any one of Items 1 to 10, which is one or more selected from the group consisting of ultraviolet absorbers based on UV absorbers, imidazole sulfonic acid derivative ultraviolet absorbers, and benzophenone derivative ultraviolet absorbers.
Item 12.
The ultraviolet absorber is 2-ethylhexyl para-methoxycinnamate, 4-tert-butyl-4'-methoxydibenzoylmethane, 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoic acid hexyl ester, 2,4 -bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5
- triazine, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine, 2-phenylbenzimidazole-5-sulfonic acid Item 12. The skin external composition according to any one of Items 1 to 11, which comprises one or more types.
Item 13.
Item 13. The skin external composition according to any one of Items 1 to 12, further comprising 0.001 to 10% by mass of a whitening ingredient.
Section 14.
Item 14. The skin external composition according to any one of Items 1 to 13, further comprising 0.001 to 5% by mass of an anti-inflammatory component.
Item 15.
Item 15. The skin external composition according to any one of Items 1 to 14, further comprising an acidic mucopolysaccharide.
Section 16.
Item 16. The external skin composition according to item 1, further comprising one or more selected from the group consisting of oil, surfactant, and thickener.

According to the present invention, it is possible to provide a composition for external use on the skin in which precipitation is suppressed.

In this specification, the unit of content "mass%" has the same meaning as "g/100g".

The skin external composition of the present invention includes:
(A) Nicotinic acid amide;
(B) a preservative; and (C) at least one member selected from the group consisting of an organic acid, an organic acid salt, a derivative of an organic acid, and an amphipathic compound.

[(A) Nicotinic acid amide]
The nicotinamide contained in the skin external composition of the present invention is nicotinic acid (vitamin B ₃ /
It is an amide compound of niacin) and is a water-soluble vitamin. Nicotinic acid amide may be an extract from a natural product or a product synthesized by a known method. Specifically, those listed in the 17th edition of the Japanese Pharmacopoeia can be used. Blood circulation promoting effect,
In addition to improving rough skin, it is known to inhibit melanin production and whiten skin.

In the skin external composition of the present invention, the content of component (A) relative to the total amount of the composition is appropriately set depending on the balance with other components. The content of component (A) is based on the total amount of the composition,
From the viewpoint of providing sufficient efficacy for whitening, anti-aging, etc., the content is preferably 3% by mass or more, more preferably 4% by mass or more, and even more preferably 5% by mass or more. Further, the content of component (A) is preferably 20% by mass or less, more preferably 15% by mass or less, even more preferably 10% by mass or less, particularly preferably 8% by mass, based on the total amount of the composition. % or less. The content of component (A) is preferably 3% to 20% by mass, more preferably 3% to 15% by mass, and even more preferably 3% to 10% by mass, based on the total amount of the composition. and even more preferably 4% to 8% by weight.

[(B) Preservative]
The preservative contained in the external skin composition of the present invention is a compound commonly used as a component of external skin preparations in the pharmaceutical, quasi-drug, or cosmetic fields, and is solid at room temperature (20°C) and water-soluble. It is a water-soluble preservative that can be dissolved in water. As used herein, the term "water-soluble preservative" may be any preservative that can be even slightly dissolved in water. For example, it is sufficient if it can be dissolved in water at a rate of 0.01% or more, preferably 0.05% or more. Examples of preservatives contained in the skin external composition of the present invention include paraoxybenzoic acid esters (parabens) such as methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, and butyl paraoxybenzoate; benzoic acid; Benzoates such as sodium benzoate; dehydroacetic acid or dehydroacetate salts such as sodium dehydroacetate; in addition, thymol, isopropylmethylphenol, caprylic hydroxamic acid, propynyl butylcarbamate iodide,
or salts or derivatives of propynyl iodide butylcarbamate; examples include sorbic acid or sorbate salts such as potassium sorbate, chlorobutanol, and methylisothiazoline.

Here, the salt of component (B) of the present invention is preferably an alkali metal salt such as sodium or potassium. As component (B) of the present invention, any one of these compounds or a combination of two or more of these compounds can be used, and among them, paraoxybenzoic acid ester, benzoic acid, benzoate, dehydroacetic acid, dehydroacetate , isopropyl methylphenol, caprylic hydroxamic acid, propynyl butylcarbamate iodide, salts or derivatives of propynyl butylcarbamate iodide, sorbic acid, sorbate, chlorobutanol, and methylisothiazoline. Preferably, methyl paraoxybenzoate,
From the group consisting of ethyl paraoxybenzoate, propyl paraoxybenzoate, benzoic acid, sodium benzoate, isopropylmethylphenol, caprylic hydroxamic acid, propynyl butyl carbamate iodide, sorbic acid, sodium sorbate, potassium sorbate, and chlorobutanol One or more selected types are more preferable, including methyl paraoxybenzoate,
One species selected from the group consisting of ethyl paraoxybenzoate, propyl paraoxybenzoate, benzoic acid, sodium benzoate, isopropylmethylphenol, caprylic hydroxamic acid, propynyl iodide butylcarbamate, sorbic acid, potassium sorbate, and chlorobutanol The above are more preferred, and one or more selected from the group consisting of methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, benzoic acid, caprylic hydroxamic acid, propynyl iodide butylcarbamate, sorbic acid, and chlorobutanol are further preferred. More preferred is one or more selected from the group consisting of methyl paraoxybenzoate, ethyl paraoxybenzoate, benzoic acid, and sorbic acid.

These can be synthesized or commercially available products can be used as they are. Such component (B) is a commercially available product, and is not particularly limited. For example, in addition to available reagents, Meccins M, ethyl paraoxybenzoate, Meccins P, butyl paraoxybenzoate (paraoxybenzoic acid ester) (all methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate (all manufactured by API Corporation); isopropyl methylphenol, thymol (all manufactured by Osaka Kasei Co., Ltd.), I
PMP-TN (manufactured by Technoble); Zeastat, Spectrastat E,
G, etc. (caprylic hydroxamic acid) (all manufactured by INOLEX); GLYCASIL,
GLYCASIL 2000, GLYCASIL L, GLYCASIL S (propynyl butylcarbamate iodide) (all manufactured by Lonza); chloretone (chlorobutanol) (manufactured by Sekisui Medical), etc. are used.

In the skin external composition of the present invention, the total content of component (B) based on the total amount of the composition is preferably 0.0001 to 6% by mass, more preferably 0.001 to 3% by mass, and still more preferably 0.0001 to 6% by mass. 01 to 1.5% by weight, even more preferably 0.05 to 1% by weight, particularly preferably 0.1 to 0.5% by weight.

In the skin external composition of the present invention, the ratio of the total content of component (B) to component (A) is not particularly limited, but it is preferable that component (B) is 0% to 1 part by mass of component (A). .00
01 to 2 parts by mass, more preferably 0.001 to 1 part by mass, even more preferably 0.01 to 0
．． 5 parts by mass.

In the skin external composition of the present invention, the total content of paraoxybenzoic acid ester relative to the total amount of the composition is not particularly limited as long as the effects of the present invention are achieved. The total content of paraoxybenzoic acid ester is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, still more preferably 0.01% by mass or more, and More preferably, it is 0.05% by mass or more, particularly preferably 0.1% by mass or more. Further, the content of paraoxybenzoic acid ester is preferably 1% by mass or less, more preferably 0.7% by mass or less, even more preferably 0.5% by mass or less, and even more preferably, based on the total amount of the composition. It is preferably 0.3% by mass or less, particularly preferably 0.2% by mass or less. Further, the total content of paraoxybenzoic acid ester is preferably 0.005 to 1% by mass, more preferably 0.01 to 0.5% by mass, even more preferably still more. Preferably, it is 0.05 to 0.3% by weight, particularly preferably 0.1 to 0.2% by weight.

In the skin external composition of the present invention, the content of benzoic acid or sodium benzoate alone relative to the total amount of the composition is not particularly limited as long as the effects of the present invention are achieved. The content of benzoic acid or sodium benzoate is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, even more preferably 0.01% by mass or more, based on the total amount of the composition. Even more preferably, it is 0.05% by mass or more. Further, the content of benzoic acid or sodium benzoate is preferably 1% by mass or less, more preferably 0.7% by mass or less, even more preferably 0.5% by mass or less, based on the total amount of the composition. Even more preferably 0.3% by mass
It is as follows. Further, the total content of benzoic acid or sodium benzoate is preferably 0.005 to 1% by mass, more preferably 0.01 to 0.5% by mass, and even more preferably, It is 0.05 to 0.3% by mass.

[(C) Component]
Component (C) contained in the skin external composition of the present invention is at least one selected from the group consisting of organic acids, organic acid salts, organic acid derivatives, and amphipathic compounds.

((C-1) Organic acid, organic acid salt, or organic acid derivative)
As the organic acid, organic acid salt, or organic acid derivative used in the present invention, compounds commonly used as components of external skin preparations in the pharmaceutical, quasi-drug, or cosmetic fields can be used.

In the present invention, an organic acid is one having an organic group and having a molecular weight of 1000 or less, preferably 700 or less, more preferably 500 or less, even more preferably 350 or less, particularly preferably 30
It is an acid of an organic compound of 0 or less. The organic acid is preferably a water-soluble organic acid. As an organic acid,
It may be a carboxylic acid having a carboxyl group, a sulfonic acid having a sulfo group, or a phosphoric acid ester having a phosphoric acid group. More specifically, examples of organic acids include, but are not limited to, ascorbic acid, tranexamic acid, citric acid, salicylic acid, lactic acid, tartaric acid, malic acid, succinic acid, oxalic acid, gluconic acid, fumaric acid, and aspartic acid. , pyrrolidonecarboxylic acid, ε-aminocaproic acid, glutamic acid, aminoethylsulfonic acid, ellagic acid, kojic acid, glycyrrhizic acid, glycyrrhetinic acid, phytic acid, ferulic acid, glycolic acid, azelaic acid, and the like. Among them, ascorbic acid, tranexamic acid, citric acid,
Salicylic acid, lactic acid, tartaric acid, malic acid, succinic acid, gluconic acid, aspartic acid, pyrrolidonecarboxylic acid, ε-aminocaproic acid, glutamic acid, aminoethylsulfonic acid, ellagic acid, kojic acid, glycyrrhizic acid, glycyrrhetinic acid, phytic acid, ferulic acid Preferably, one or more selected from the group consisting of acid, glycolic acid, and azelaic acid, including ascorbic acid, tranexamic acid, citric acid, salicylic acid, lactic acid, tartaric acid, malic acid, succinic acid, gluconic acid, pyrrolidonecarboxylic acid, More preferably, one or more selected from the group consisting of ε-aminocaproic acid, glutamic acid, kojic acid, glycyrrhizic acid, glycyrrhetinic acid, phytic acid, ferulic acid, glycolic acid, and azelaic acid, and ascorbic acid, tranexamic acid, and citric acid. One or more acids selected from the group consisting of salicylic acid, lactic acid, succinic acid, tartaric acid, gluconic acid, kojic acid, phytic acid, glycolic acid, and glycyrrhizinic acid are more preferred, and ascorbic acid, tranexamic acid, and citric acid. , lactic acid, gluconic acid, salicylic acid, tartaric acid, phytic acid, and kojic acid, and one or more selected from the group consisting of ascorbic acid, tranexamic acid, citric acid, and lactic acid are even more preferred. One species or two or more species are particularly preferred.

In the present invention, an organic acid salt refers to a salt of such an organic acid. The salt forming the organic acid salt is a pharmaceutically acceptable salt. For example, but not limited to, salts with organic bases (e.g., salts with tertiary amines such as trimethylamine salt, triethylamine salt, monoethanolamine salt, triethanolamine salt, pyridine salt; bases such as arginine or lysine) salts with inorganic bases (e.g., inorganic acid salts such as hydrochlorides, sulfates, and phosphates; ammonium salts; alkali metal salts such as sodium salts and potassium salts; calcium salts, magnesium salts, etc.) alkaline earth metal salts; or zinc salts, aluminum salts, etc.). Among these, preferred organic acid salts are triethanolamine salts, monoammonium salts, sodium salts, potassium salts, dipotassium salts, magnesium salts, or zinc salts, and particularly preferred organic acid salts are sodium salts, dipotassium salts, or magnesium salts. It is.

In the present invention, preferred organic acid salts include sodium ascorbate, tranexamic hydrochloride, calcium tranexamate, sodium salicylate, calcium salicylate, magnesium salicylate, potassium salicylate, sodium lactate, sodium tartrate, sodium citrate, disodium citrate, Trisodium citrate, potassium citrate, sodium succinate, disodium succinate, sodium oxalate, calcium gluconate,
Zinc gluconate, sodium pyrrolidone carboxylate, zinc pyrrolidone carboxylate, sodium glutamate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate,
Examples include sodium phytate, sodium glycolate, and ammonium glycolate. Among them, sodium ascorbate, tranexamic hydrochloride, calcium tranexamate, sodium salicylate, sodium lactate, sodium tartrate, sodium citrate, disodium citrate, trisodium citrate, sodium succinate, disodium succinate, calcium gluconate, The group consisting of zinc gluconate, zinc pyrrolidone carboxylate, sodium pyrrolidone carboxylate, sodium glutamate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, sodium phytate, sodium glycolate, ammonium glycolate, and sodium succinate, disodium succinate. Preferably, one or more selected from the following are sodium ascorbate, sodium salicylate, sodium lactate, sodium citrate, disodium citrate, trisodium citrate, zinc gluconate, sodium pyrrolidone carboxylate, sodium glutamate, and succinic acid. More preferably, one or more selected from the group consisting of sodium and disodium succinate, and one selected from the group consisting of sodium ascorbate, sodium lactate, sodium citrate, sodium succinate, and disodium succinate. One species or two or more species are even more preferred.

In the present invention, the term "organic acid derivative" refers to such an organic acid derivative, and the molecular weight is 100.
0 or less, preferably 800 or less, more preferably 600 or less, even more preferably 5
00 or less, particularly preferably 450 or less, and most preferably 350 or less, acid derivatives of organic compounds. The organic acid derivative is preferably a water-soluble organic acid derivative.

In the present invention, the organic acid derivatives include ascorbic acid phosphate esters such as sodium ascorbic acid phosphate and magnesium ascorbic acid phosphate; ascorbic acid sulfate esters such as disodium ascorbic acid sulfate; 2-O-ethyl Alkyl ascorbic acids such as ascorbic acid and 3-O-ethyl ascorbic acid; ascorbic acid glycosides such as ascorbic acid-2-glucoside; disodium isostearyl ascorbyl phosphate, trisodium palmitate ascorbyl phosphate; glyceryl ascorbic acid, Bisglyceryl ascorbic acid, alkylglyceryl ascorbic acid; (ascorbyl/tocopheryl) phosphoric acid, (ascorbyl/tocopheryl) potassium phosphate, ascorbyl tocopheryl maleate; ascorbyl tetrahexyl decanoate, dipalmitic acid L
- Oil-soluble ascorbic acid derivatives such as ascorbyl; Dimers of tranexamic acid; Amides of tranexamic acid such as tranexamic acid methylamide hydrochloride; Hydroquinone ester of tranexamic acid; Vitamin esters such as vitamin A ester, vitamin E ester, and vitamin C ester , alkyl esters and other tranexamic acid vitamin esters; tranexamic acid gentisic acid ester; tranexamic acid cetyl hydrochloride; polyhydric alcohol esters such as ethylene glycol salicylate and dipropylene glycol salicylate; alkyl salicylates such as methyl salicylate and 2-ethylhexyl salicylate; Alcosylsalicylic acid, such as 4-methoxysalicylic acid, potassium 4-methoxysalicylate, or its salt; acyl amino acid or its salt, such as sodium stearoylglutamate, sodium lauroylglutamate, sodium dilauroylglutamate lysine; and stearyl glycyrrhetinate. One or more types are included. Among them, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, disodium ascorbic acid sulfate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside, isostearyl ascorbyl phosphate. Disodium, trisodium ascorbyl palmitate phosphate, glyceryl ascorbic acid, bisglyceryl ascorbic acid, hexyl 3-glyceryl ascorbic acid, 3-glyceryl ascorbic acid, myristyl 3-glyceryl ascorbic acid, 3-lauryl glyceryl ascorbic acid, (ascorbyl/ Tocopheryl) phosphate, (ascorbyl/tocopheryl) potassium phosphate, ascorbyl tocopheryl maleate, tranexamic acid methylamide hydrochloride, tranexamic acid cetyl hydrochloride, ethylene glycol salicylate, methyl salicylate, 2-ethylhexyl salicylate, 4-methoxysalicylic acid, 4 - Preferably one or more selected from the group consisting of potassium methoxysalicylate, sodium stearoylglutamate, sodium lauroylglutamate, sodium lysine dilauroylglutamate, and stearyl glycyrrhetinate, sodium ascorbic acid phosphate, and ascorbic acid phosphate. Magnesium, disodium ascorbic acid sulfate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside, disodium isostearyl ascorbyl phosphate, trisodium palmitate ascorbyl phosphate, glyceryl ascorbic acid Acid, bisglyceryl ascorbic acid, hexyl 3-glyceryl ascorbic acid, 3-glyceryl ascorbic acid, myristyl 3-glyceryl ascorbic acid, 3-lauryl glyceryl ascorbic acid, 4-methoxysalicylic acid, potassium 4-methoxysalicylate, sodium stearoylglutamate, lauroyl More preferably, one or more selected from the group consisting of sodium glutamate and sodium lysine dilauroylglutamate, including sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, disodium ascorbic acid sulfate, and 2-O- Ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside,
One or more selected from the group consisting of glyceryl ascorbic acid, bisglyceryl ascorbic acid, hexyl 3-glyceryl ascorbic acid, 3-glyceryl ascorbic acid, potassium 4-methoxysalicylate, sodium stearoylglutamate, and sodium lysine dilauroylglutamate. More preferred are sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, and ascorbic acid sulfate 2.
Even more preferred is one or more selected from the group consisting of sodium, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, and ascorbic acid-2-glucoside.

These can be synthesized or commercially available products can be used as they are.

These organic acids, organic acid salts, or organic acid derivatives may be used alone or in combination of two or more.

Here, in particular, when component (B) is paraoxybenzoic acid ester, component (C-1) contains ascorbic acid, ascorbate, alkyl ascorbate, ascorbic acid phosphate, and ascorbic acid glycoside. In the case, ascorbic acid, sodium ascorbate, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, disodium ascorbic acid sulfate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid -2-glucoside, disodium isostearyl ascorbyl phosphate, trisodium ascorbyl palmitate phosphate, glyceryl ascorbic acid, bisglyceryl ascorbic acid, hexyl 3-glyceryl ascorbic acid, 3-glyceryl ascorbic acid, myristyl 3-glyceryl ascorbic acid, Whitening and Also preferred from the viewpoint of antioxidant effect, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, disodium ascorbic acid sulfate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid- It is more preferable to combine two or more different components selected from the group consisting of 2-glucosides.

Component (C-1) of the present invention includes ascorbic acid, tranexamic acid, citric acid, salicylic acid, lactic acid, acetic acid, tartaric acid, malic acid, succinic acid, oxalic acid, gluconic acid, fumaric acid, propionic acid, aspartic acid, and pyrrolidone. Carboxylic acid, ε-aminocaproic acid, glutamic acid, aminoethyl sulfonic acid, ellagic acid, kojic acid, glycyrrhizic acid, glycyrrhetinic acid, phytic acid, ferulic acid, glycolic acid, azelaic acid, ascorbic acid phosphate, ascorbic acid sulfate, Alkyl ascorbic acid, ascorbic acid glycoside, isostearyl ascorbyl phosphate disodium, palmitate ascorbyl phosphate 3
Sodium, glyceryl ascorbic acid derivatives, tranexamic acid dimers, tranexamic acid amides, tranexamic acid esters, alkyl tranexamic acids, salicylic acid polyhydric alcohol esters, alkyl salicylates, alkosylsalicylic acids, acylamino acids, glycyrrhetinic acid esters, and these One or more salts selected from the group consisting of salts of ascorbic acid, tranexamic acid, citric acid, salicylic acid, lactic acid, tartaric acid, malic acid, succinic acid, gluconic acid, pyrrolidonecarboxylic acid, ε-aminocaproic acid, Glutamic acid, kojic acid, glycyrrhetinic acid, phytic acid, ferulic acid, glycolic acid, azelaic acid, sodium ascorbate, tranexamic hydrochloride, calcium tranexamic acid, sodium salicylate, sodium lactate, sodium tartrate, sodium citrate, disodium citrate , trisodium citrate, sodium succinate, disodium succinate, calcium gluconate, zinc gluconate, sodium pyrrolidone carboxylate, zinc pyrrolidone carboxylate, sodium glutamate, sodium phytate, sodium glycolate, ammonium glycolate, glycyrrhizic acid Dipotassium, monoammonium glycyrrhizinate, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, disodium ascorbic acid sulfate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside , disodium isostearyl ascorbyl phosphate, trisodium ascorbyl palmitate phosphate, glyceryl ascorbic acid, bisglyceryl ascorbic acid, hexyl 3-glyceryl ascorbic acid, 3-glyceryl ascorbic acid, myristyl 3-glyceryl ascorbic acid, 3-
Lauryl glyceryl ascorbic acid, potassium (ascorbyl/tocopheryl) phosphate,
and ascorbyl tocopheryl maleate, tranexamic acid methylamide hydrochloride, cetyl tranexamic acid hydrochloride, ethylene glycol salicylate, methyl salicylate, 2-ethylhexyl salicylate, 4-methoxysalicylic acid, potassium 4-methoxysalicylate, sodium stearoylglutamate, sodium lauroylglutamate, More preferably, one or more selected from the group consisting of lysine sodium dilauroylglutamate and stearyl glycyrrhetinate, including ascorbic acid, tranexamic acid, citric acid, salicylic acid, lactic acid, gluconic acid, kojic acid, tartaric acid, phytic acid, Glycolic acid, sodium ascorbate, sodium salicylate, sodium lactate, sodium citrate, disodium citrate, trisodium citrate, sodium succinate, disodium succinate, sodium pyrrolidonecarboxylate, sodium glutamate, dipotassium glycyrrhizinate, glycyrrhizic acid Monoammonium, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside, sodium stearoyl glutamate, sodium lauroyl glutamate, dilauroyl More preferably, one or more selected from the group consisting of sodium lysine glutamate, including citric acid, lactic acid, tranexamic acid, salicylic acid, gluconic acid, phytic acid, tartaric acid, sodium lactate, sodium citrate, and sodium ascorbic acid phosphate. , ascorbic acid phosphate magnesium, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside, sodium succinate, disodium succinate, are even more preferred, and tranexamic acid, citric acid , lactic acid, salicylic acid, gluconic acid, phytic acid, tartaric acid,
One member selected from the group consisting of disodium succinate, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, and ascorbic acid-2-glucoside. Or two or more types are particularly preferable.

In the skin external composition of the present invention, the total content of organic acids, organic acid salts, or organic acid derivatives based on the total amount of the composition is preferably 0.001 to 10% by mass, more preferably 0.00% by mass.
5 to 7% by weight, more preferably 0.01 to 5% by weight, even more preferably 0.05 to 5% by weight
5% by weight, particularly preferably 0.1-3% by weight.

In the skin external composition of the present invention, the ratio of the total content of organic acid, organic acid salt, or organic acid derivative to component (A) is not particularly limited, but with respect to 1 part by mass of component (A), The amount of the organic acid, organic acid salt, or organic acid derivative is preferably 0.001 to 3.5 parts by weight, more preferably 0.01 to 2 parts by weight, and even more preferably 0.05 to 1 part by weight.

In the skin external composition of the present invention, the total content of ascorbic acid, salts thereof, or derivatives thereof is not particularly limited, but is preferably 0.001 to 10% by mass, more preferably 0.01 to 7% by mass. %, more preferably 0.05 to 5% by weight, even more preferably 0.
It is 1 to 5% by weight, particularly preferably 0.5 to 3% by weight.
In the skin external composition of the present invention, the total content of tranexamic acid, salts thereof, or derivatives thereof is not particularly limited, but is preferably 0.1 to 5% by mass, more preferably 0.5% by mass.
~5% by weight, more preferably 1~3% by weight.

((C-2) Amphipathic compound)
The amphipathic component contained in the skin external composition as component (C-2) of the present invention has both a hydrophilic group and a hydrophobic group (lipophilic group) in one molecule, and as a result, the aqueous phase and oil Refers to all compounds that have an affinity for any phase (organic phase).

Such amphiphilic compounds are not particularly limited, but include, for example, alkylene oxide derivatives, phosphorylcholine-containing polymers, divalent carboxylic acid esters, or carbon atoms of 5 to 1.
0 alkanediol and the like. As component (C-2) of the present invention, any of these compounds may be used alone or in combination of two or more. By blending component (C-2) with component (A) and component (B), a composition for external use on the skin is provided in which precipitation is suppressed even when a high concentration of nicotinic acid amide is blended. becomes possible.

Component (C-2) is preferably an alkylene oxide derivative represented by the following general formula (I), a 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer,
(eicosandioic acid/tetradecanedioic acid) one selected from the group consisting of decaglyceryl, bisethoxydiglycol cyclohexanedicarboxylate, diethylhexyl succinate, diethoxyethyl succinate, and alkanediols having 5 to 10 carbon atoms; or There are two or more types.

（式中、
Ｚは、水素原子、又は、炭素数１～３０のヒドロキシ化合物からｎ個のヒドロキシ基を
除去することによって得られる残基を意味し；
ＡＯは、３～４個の炭素原子を有するオキシアルキレン基を意味し；
ＥＯは、オキシエチレン基を意味し；
ＢＯは、４個の炭素原子を有するオキシアルキレン基を意味し；
ｎは、１～９を意味し；
ａ，ｂ及びｃは、それぞれＡＯ、ＥＯ、ＢＯの平均付加モル数を意味し、独立して０～
２００である。但し、ａ、ｂ及びｃが全て０になることはない。また、ｎが２以上の時、
複数のａ、ｂ及びｃはそれぞれ同一でも異なってもよい。Ｚが水素原子の時はｎは１であ
る。
なお、ＡＯ及びＥＯは、ランダムに又はブロックの形態で付加されていてよい。）

(In the formula,
Z means a hydrogen atom or a residue obtained by removing n hydroxy groups from a hydroxy compound having 1 to 30 carbon atoms;
AO means an oxyalkylene group having 3 to 4 carbon atoms;
EO means oxyethylene group;
BO means an oxyalkylene group having 4 carbon atoms;
n means 1 to 9;
a, b and c mean the average number of added moles of AO, EO, and BO, respectively, and independently range from 0 to
It is 200. However, a, b, and c will not all be 0. Also, when n is 2 or more,
A plurality of a, b and c may be the same or different. When Z is a hydrogen atom, n is 1.
Note that AO and EO may be added randomly or in the form of blocks. )

From the viewpoint of providing a good composition for external use on the skin, the alkylene oxide derivatives include:
A compound represented by the following general formula (II) is preferable.

（式中、
Ｚは、水素原子、又は、炭素数１～３０のヒドロキシ化合物からｎ個のヒドロキシ基を
除去することによって得られる残基を意味し；
ＡＯは、３～４個の炭素原子を有するオキシアルキレン基を意味し；
ＥＯは、オキシエチレン基を意味し；
ｎは、１～９を意味し；
ａ及びｂは、それぞれＡＯ、ＥＯの平均付加モル数を意味し、独立して０～２００であ
る。但し、ａ及びｂが全て０になることはない。また、ｎが２以上の時、複数のａ、ｂは
それぞれ同一でも異なってもよい。Ｚが水素原子の時はｎは１である。
なお、ＡＯ及びＥＯは、ランダムに又はブロックの形態で付加されていてよい。）

(In the formula,
Z means a hydrogen atom or a residue obtained by removing n hydroxy groups from a hydroxy compound having 1 to 30 carbon atoms;
AO means an oxyalkylene group having 3 to 4 carbon atoms;
EO means oxyethylene group;
n means 1 to 9;
a and b mean the average number of added moles of AO and EO, respectively, and independently range from 0 to 200. However, a and b are never all 0. Further, when n is 2 or more, the plurality of a's and b's may be the same or different. When Z is a hydrogen atom, n is 1.
Note that AO and EO may be added randomly or in the form of blocks. )

The alkylene oxide derivative used in the present invention is a specific alkylene glycol polymer (when Z is a hydrogen atom) or a specific hydroxy compound (corresponding to Z) with a specific alkylene oxide group (general formula (I)). and (corresponding to the moiety excluding Z in (II)) (when Z is a group obtained by removing n hydroxy groups from a hydroxy compound having 1 to 30 carbon atoms).

In the alkylene oxide derivative used in the present invention, from the viewpoint of providing a skin external composition with suppressed precipitation, AO is an oxyalkylene group having 3 to 4 carbon atoms, and for example,
Examples include oxypropylene group, oxybutylene group (oxy n-butylene group, oxyisobutylene group, oxy t-butylene group), oxytrimethylene group, oxytetramethylene group, and the like. AO is preferably an oxypropylene group, an oxybutylene group, and more preferably an oxypropylene group.

In the alkylene oxide derivative used in the present invention, BO is an oxyalkylene group having 4 carbon atoms, such as oxybutylene group (oxy n-butylene group, oxyisobutylene group, oxy t-butylene group), oxytetramethylene group, etc. Examples include groups. Preferably it is an oxybutylene group.

In the alkylene oxide derivative used in the present invention, a, b, and c each independently range from 0 to 200. a, b, and c are each independently preferably from 1 to 200, more preferably from 2 to 150, still more preferably from 2 to 100, particularly preferably from 2 to 70.

In chemical formula (I), a+b+c which is the total number of monomer units of AO, EO, and BO
is preferably 3 or more, more preferably 5 or more, from the viewpoint of significantly achieving the effects of the present invention,
More preferably, it is 10 or more. In addition, a+b+c is preferably 450 or less, more preferably 350 or less, still more preferably 300 or less, from the viewpoint of significantly achieving the effects of the present invention.
Particularly preferably, it is 250 or less.

In chemical formula (II), a+b, which is the total number of monomer units of AO and EO, is preferably 3 or more, more preferably 5 or more, and still more preferably 10 or more, from the viewpoint of significantly achieving the effects of the present invention. . Further, a+b is preferably 400 or less, more preferably 300 or less, still more preferably 250 or less, and particularly preferably 200 or less, from the viewpoint of significantly achieving the effects of the present invention.

In the formulas (I) and (II), from the viewpoint of providing a skin external composition with suppressed precipitation, Z is a hydrogen atom or an alkyl monoalcohol having 4 to 24 carbon atoms,
From glycerin, trimethylolpropane, erythritol, pentaerythritol, alkyl glucosides having 1 to 24 carbon atoms, diglycerin, xylitol, dipentaerythritol, sorbitol, inositol, sucrose, trehalose, or maltitol
It is preferably a residue obtained by removing a hydroxyl group, that is, a residue derived from these alcohol compounds, and is a hydrogen atom or an alkyl monoalcohol having 4 to 24 carbon atoms, Glycerin (3 hydroxy groups to which alkylene oxide groups can be attached), pentaerythritol (4 hydroxy groups to which alkylene oxide groups can be attached), alkyl glucosides having 1 to 24 carbon atoms (hydroxy groups to which alkylene oxide groups can be attached) It is obtained by removing n hydroxy groups from diglycerin (4 hydroxy groups to which an alkylene oxide group can be attached) or sorbitol (6 hydroxy groups to which an alkylene oxide group can be attached). More preferably, it is a hydrogen atom, or n hydroxy groups from a C4-C24 alkyl monoalcohol, glycerin, a C1-C24 alkyl glucoside, diglycerin, or sorbitol. More preferably, it is a residue obtained by removing a hydrogen atom, or a residue obtained by removing n atoms from an alkyl monoalcohol having 4 to 24 carbon atoms, glycerin, an alkyl glucoside having 1 to 5 carbon atoms, or diglycerin. More preferably, it is a residue obtained by removing the hydroxy group of , and a residue obtained by removing n hydroxy groups from an alkyl monoalcohol having 4 to 24 carbon atoms, glycerin, or diglycerin. It is even more preferable.

In chemical formula (I) or (II), when Z is an alkyl monoalcohol having 4 to 24 carbon atoms, butyl alcohol, tetradecyltetraalcohol, cetanol, and stearyl alcohol are preferable from the viewpoint of exhibiting the effects of the present invention. , butyl alcohol and tetradecyltetraalcohol are particularly preferred.

In chemical formula (I) or (II), when Z is an alkyl glucoside, alkyl glucosides having 1 to 24 carbon atoms are preferred, and alkyl glucosides having 1 to 16 carbon atoms are preferred, from the viewpoint of exhibiting the effects of the present invention significantly. More preferred are alkyl glucosides having 1 to 10 carbon atoms, even more preferred are alkyl glucosides having 1 to 5 carbon atoms.

Such alkylene oxide derivatives can be synthesized by known methods. For example, it can be obtained by addition-polymerizing a hydroxy compound having 1 to 30 carbon atoms with ethylene oxide and an alkylene oxide having 3 to 4 carbon atoms, and then reacting the alkylene oxide with 4 carbon atoms. In addition, ethylene oxide and hydroxy compound having 1 to 30 carbon atoms are added.
In the step of addition polymerizing alkylene oxide having 3 to 4 carbon atoms, ethylene oxide and alkylene oxide may be randomly polymerized or block polymerized. For the addition reaction, an alkali catalyst, a phase transfer catalyst, a Lewis acid catalyst, etc. can be used. Generally, it is preferable to use an alkali catalyst such as potassium hydroxide.

The molecular weight of such an alkylene oxide derivative is not limited as long as it achieves the effects of the present invention, but from the viewpoint of significantly achieving the effects of the present invention, it is preferably 200 or more, more preferably 300 or more, More preferably, it is 400 or more.

The properties of the alkylene oxide derivative are not limited as long as they exhibit the effects of the present invention, but in formulas (I) and (II), from the viewpoint of significantly exhibiting the effects of the present invention, preferably:
Preferably, the component is in a semi-solid state (including a pasty state) to a liquid state at 25°C.

Further, such alkylene oxide derivatives include, for example, polyoxyalkylene glyceryl ether, polyoxyalkylene alkyl glucoside, polyoxypropylene alkyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene polyoxypropylene oxybutylene alkyl ether, Polyoxyalkylene sorbitol, polyoxyalkylene erythritol ether, polyoxyalkylene pentaerythritol ether, polyoxyalkylene diglyceryl ether, polyoxyalkylene trimethylolpropane, polyoxypropylene glycol, polyoxyethylene polyoxypropylene glycol, polyoxyalkylene xylitol, Examples include polyoxyalkylene dipentaerythritol, polyoxyalkylene inositol, polyoxyalkylene sucrose ether, polyoxyalkylene trehalose ether, polyoxyalkylene maltitol ether, and the like.

Among them, alkylene oxide derivatives include polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether, polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene alkyl Glucoside, polyoxyethylene polyoxypropylene alkyl glucoside, polyoxyethylene alkyl glucoside, polyoxypropylene alkyl glucoside, polyoxypropylene alkyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxypropylene sorbitol, polyoxyethylene sorbitol, polyoxy Ethylene polyoxypropylene sorbitol, polyoxypropylene erythritol ether, polyoxyethylene erythritol ether, polyoxyethylene pentaerythritol ether, polyoxyethylene polyoxypropylene erythritol ether, polyoxypropylene pentaerythritol ether, polyoxyethylene polyoxypropylene pentaerythritol ether , polyoxybutylene polyoxyethylene pentaerythritol ether, polyoxyethylene diglyceryl ether, polyoxypropylene diglyceryl ether, polyoxyethylene polyoxypropylene diglyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene diglyceryl ether, polyoxy Ethylene trimethylol propane, polyoxypropylene trimethylol propane, polyoxyethylene polyoxypropylene trimethylol propane, polyoxypropylene glycol, polyoxyethylene polyoxypropylene glycol, polyoxybutylene polyoxyethylene polyoxypropylene glycol, polyoxyethylene xylitol , polyoxypropylene alkylene xylitol, polyoxyethylene polyoxypropylene xylitol, polyoxyethylene polyoxypropylene dipentaerythritol, polyoxyethylene dipentaerythritol, polyoxypropylene dipentaerythritol,
Polyoxyethylene inositol, polyoxypropylene inositol, polyoxyethylene polyoxypropylene inositol, polyoxyethylene sucrose ether, polyoxypropylene sucrose ether, polyoxyethylene polyoxypropylene sucrose ether, polyoxyethylene trehalose ether, polyoxypropylene trehalose ether , polyoxyethylene polyoxypropylene rehalose ether, polyoxyethylene maltitol ether, polyoxypropylene maltitol ether, and polyoxyethylene polyoxypropylene maltitol ether, preferably one or more selected from the group consisting of
Polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether,
Polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene alkyl glucoside, polyoxyethylene alkyl glucoside, polyoxypropylene alkyl glucoside, polyoxypropylene alkyl ether , polyoxyethylene polyoxypropylene alkyl ether, polyoxypropylene sorbitol, polyoxyethylene sorbitol, polyoxyethylene polyoxypropylene pentaerythritol ether, polyoxypropylene pentaerythritol ether, polyoxyethylene pentaerythritol ether, polyoxybutylene polyoxyethylene Pentaerythritol ether, polyoxyethylene diglyceryl ether, polyoxypropylene diglyceryl ether, polyoxyethylene polyoxypropylene diglyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene diglyceryl ether, polyoxyethylene polyoxypropylene trimethylol propane , polyoxypropylene glycol, polyoxyethylene polyoxypropylene glycol,
and more preferably one or more selected from the group consisting of polyoxybutylene polyoxyethylene polyoxypropylene glycol,
Polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether,
Polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene alkyl glucoside, polyoxypropylene alkyl glucoside, polyoxyethylene alkyl glucoside, polyoxypropylene alkyl ether , polyoxyethylene polyoxypropylene alkyl ether, polyoxypropylene sorbitol, polyoxyethylene polyoxypropylene sorbitol, polyoxyethylene diglyceryl ether, polyoxypropylene diglyceryl ether, polyoxyethylene polyoxypropylene diglyceryl ether, polyoxybutylene More preferably, one or more selected from the group consisting of polyoxyethylene polyoxypropylene diglyceryl ether, polyoxypropylene glycol, polyoxyethylene polyoxypropylene glycol, and polyoxybutylene polyoxyethylene polyoxypropylene glycol. ,
Polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether,
Polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene alkyl glucoside, polyoxypropylene alkyl glucoside, polyoxyethylene alkyl glucoside, polyoxypropylene alkyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxy One or two selected from the group consisting of propylene sorbitol, polyoxyethylene polyoxypropylene sorbitol, polyoxyethylene diglyceryl ether, polyoxypropylene diglyceryl ether, and polyoxyethylene polyoxypropylene diglyceryl ether.
More preferably, polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether, polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene methyl glucoside, polyoxypropylene methyl glucoside, polyoxyethylene methyl Consisting of glucoside, polyoxypropylene alkyl ether, polyoxyethylene polyoxypropylene butyl ether, polyoxyethylene polyoxypropylene decyltetradecyl ether, polyoxypropylene sorbitol, polyoxypropylene diglyceryl ether, polyoxyethylene polyoxypropylene diglyceryl ether One or more selected from the group is even more preferred.

These alkylene oxide derivatives are Unilube 50MB-26 (polyoxyethylene polyoxypropylene butyl ether (17E.O.) (17P.O.)), Unilube 50MB-168 (polyoxyethylene polyoxypropylene butyl ether (37E.O.)
．． O. )( 38P.O.)), Unilube 50MB-11 (polyoxyethylene polyoxypropylene butyl ether (9E.O.) (10P.O.)), Unisafe 10P-8 (
Polyoxyethylene polyoxypropylene cetyl ether (10E.O.) (8P.O.
)), Unilube MT-630B (polyoxyethylene polyoxypropylene decyl tetradecyl ether (30E.O.) (6P.O.)), Unilube MS-70K (polyoxypropylene stearyl ether (15P.O.)), Uniall HS-1600D(
Pronone #208 (polyoxyethylene polyoxypropylene glycol (150E.O.) (35P.O.)), Pronone #124P (polyoxyethylene (20) polyoxypropylene (20) glycol), Yunior D-
2000 (polypropylene glycol), Macbiobride MG-10E (polyoxyethylene methyl glucoside (10E.O.)), Macbiobride MG-20E (polyoxyethylene methyl glucoside (20E.O.)), Macbiobride MG -10P (polyoxypropylene methyl glucoside (10P.O.), Macbiobride MG-20P (
Polyoxypropylene methyl glucoside (20P.O.)), Wilbride MG207
0 (polyoxybutylene polyoxyethylene polyoxypropylene methyl glucoside),
Unilube 5TP-300KB (polyoxyethylene polyoxypropylene pentaerythritol ether (5E.O.) (65P.O.)); Unilube 50TG-32 (polyoxyethylene polyoxypropylene glyceryl ether (24E.O.) (24P.O.) O.)
), Wilbride S-753 (polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether (3B.O.) (8E.O.) (5P.O.)), Uniox G-
1200 (polyoxyethylene glycerin (26E.O.)), Unilube DGP-70
0 (Polyoxypropylene diglyceryl ether (9P.O.)), Unilube DGP-9
50 (polyoxypropylene diglyceryl ether (14P.O.)) (manufactured by NOF Corporation); SY-DP14 (polyoxypropylene diglyceryl ether (14P.O.))
, SY-DP9 (polyoxypropylene diglyceryl ether (9P.O.)) (manufactured by Sakamoto Pharmaceutical Co., Ltd.); Newport GP-1000 (PPG-16 glyceryl ether), Newport SP-750 (polyoxy alkylene sorbitol ether), Newpol PE-68 (polyoxyethylene polyoxypropylene glycol (160E.
O. ) (30P.O.)), Newport PE-78 (polyoxyethylene polyoxypropylene glycol (150E.O.) (35P.O.)), Newport GEP-28
00 (Polyoxyethylene polyoxypropylene glyceryl ether (24E.O.) (
24P. O. )) (manufactured by Sanyo Kasei Co., Ltd.); Emulgen PP-290 (polyoxyethylene polyoxypropylene glycol (160E.O.) (30P.O.), manufactured by Kao Corporation); NIKKOL SG-G2424 (polyoxy Ethylene polyoxypropylene glyceryl ether (24E.O.) (24P.O.), NIKKOL SG-DTD
630 (polyoxyethylene polyoxypropylene decyl tetradecyl ether (30E
．． O. ) (6P.O.) (manufactured by Nikko Chemicals); GLUCAM P-10 (polyoxypropylene methyl glucoside (10P.O.)), GLUCAM P-20 (polyoxypropylene methyl glucoside (20P.O.)) GLUCAM E-10 (polyoxyethylene methyl glucoside (10E.O.)), GLUCAM E-20 (polyoxyethylene methyl glucoside (20E.O.)) (manufactured by Lubrizol), Brownon GL-26 (polyoxyethylene methyl glucoside (20E.O.)), It is commercially available under the name of oxyethylene glycerin (26E.O.) (manufactured by Aoki Yushi Kogyo Co., Ltd.).
Commercially available alkylene oxide derivatives include:
Unilube 50MB-26, Unilube 50MB-168, Unior HS-1600D
, Pronon #208, Pronon #124P, Unior D-2000, MacBioBride MG-10E, MacBioBride MG-20E, MacBioBride MG-10P, MacBioBride MG-20P, Wilbride MG2070, Wilbride S- 753, Unilube 5TP-300KB, Unilube 50TG-32, Uniox G-1200,
UNILUBE DGP-700, UNILUBE DGP-950, SY-DP14, SY-DP9
, Newport GP-1000, Newport SP-750, Newport PE-68,
Newport PE-78, Newport GEP-2800, NIKKOL SG-G24
24, GLUCAM P-10, GLUCAM P-20, GLUCAM E-10, G
Preferably, it is one or more selected from the group consisting of LUCAM E-20 and Emulgen PP-290, including Unilube 50MB-26, Unilube 50MB-168, Uniol HS-1600D, Pronon #208, Pronon #124P, Macbio. Bride MG
-10E, Macbiobride MG-20E, Macbiobride MG-10P, Macbiobride MG-20P, Wilbride MG2070, Unilube 50TG-32, SY-
DP14, SY-DP9, GLUCAM P-10, GLUCAM P-20, GLUC
AM E-10, GLUCAM E-20 Newport PE-68, Newport PE-
78, and Emulgen PP-290, and more preferably one or more selected from the group consisting of Unilube 50MB-26, Unilube 50MB-168, Macbiobride MG-10E, Macbiobride MG-20E, Macbiobride. Bride MG-10P, MacBioBride MG-20P, Pronon #208, Pronon #124P, Wilbride MG
2070, Unilube 50TG-32, SY-DP14, SY-DP9, Newport P
E-68, Newport PE-78, GLUCAM P-10, GLUCAM P-20
, GLUCAM E-10, GLUCAM E-20, and Emulgen PP-290.

In the present invention, the alkylene oxide derivatives may be used alone or in any combination of two or more.

The phosphorylcholine-containing polymer refers to all polymers containing an organic compound containing phosphorylcholine as a monomer. Although not particularly limited, a 2-methacryloyloxyphosphorylcholine-containing polymer, which is a polymer obtained by polymerizing a monomer containing 2-methacryloyloxyethylphosphorylcholine, is particularly preferred from the viewpoint of significantly exhibiting the effects of the present invention. Among these, one or more selected from the group consisting of 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer (polyquaternium-51) and polymethacryloyloxyethylphosphorylcholine are preferred, and 2-methacryloyloxyethylphosphorylcholine/methacrylate Acid butyl copolymers are more preferred. Commercially available phosphorylcholine-containing polymers include Lipidure-PMB (2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer liquid, Polyquaternium-5
1), and Lipidure-HM (polymethacryloyloxyethylphosphorylcholine) (both manufactured by NOF Corporation), preferably one or more selected from the group consisting of
pidure-PMB (2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer liquid) is more preferred.

A divalent carboxylic acid ester is an ester condensed with a divalent carboxylic acid and a hydroxyl group such as glycol or glycol ether, and examples thereof include, but are not limited to, polyglyceryl-10 (eicosanedioic acid/tetradecanedioic acid), cyclohexanedicarboxylic acid, etc. acid bisethoxydiglycol, 1,4-cyclohexanedicarboxylic acid bis(triethylene glycol monoethyl ether), adipate bis(diethylene glycol monoethyl ether), adipate bis(triethylene glycol monoethyl ether), and succinic acid diethoxy ethyl, diethylhexyl succinate, among others eicosanedioic acid/tetradecanedioic acid)
Preferred are polyglyceryl-10, bisethoxydiglycol cyclohexanedicarboxylate, diethoxyethyl succinate, and diethylhexyl succinate, more preferred are polyglyceryl-10 (eicosandioic acid/tetradecanedioic acid), bisethoxydiglycol cyclohexanedicarboxylate, and cyclohexanedicarboxylate. Even more preferred are acid bisethoxydiglycols. In addition, commercially available products include, but are not limited to, diethoxyethyl succinate (C
RODAMOL DES), diethylhexyl succinate (CRODAMOL OSU) (
Both are manufactured by Croda Japan Co., Ltd.), Neosolue-Aqua Neosolue
-AquaS ((eicosanedioic acid/tetradecanedioic acid) polyglyceryl-10), Neo
solue-Aqulio (cyclohexanedicarboxylic acid bisethoxydiglycol) (
Both products (manufactured by Nippon Fine Chemical Co., Ltd.) can be used.

From the viewpoint of exhibiting the effects of the present invention, the alkanediol preferably has 5 carbon atoms.
-10, more preferably 5-8, still more preferably 5-6. For example, 1,2-pentanediol, 1,2-hexanediol, and 1,2-octanediol are preferred;
-pentanediol and 1,2-hexanediol are more preferred, and 1,2-pentanediol is even more preferred. In addition, commercially available products include, but are not limited to, HYDROLITE
-5, HYDROLITE-5 Green (manufactured by Symrise Co., Ltd.), KMO-6 (manufactured by Osaka Organic Chemical Industry), Microcare Emolient PTGJ, Microcare Emo
llient HXD (manufactured by THOR) can be used.

In the present invention, as component (C-2), in addition to the above alkylene oxide derivatives,
2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer, polymethacryloyloxyethylphosphorylcholine, (eicosanedioic acid/tetradecanedioic acid)
Preferred are degacryceryl, bisethoxydiglycol cyclohexanedicarboxylate, diethylhexyl succinate, diethoxyethyl succinate, and alkanediols having 5 to 10 carbon atoms, and in addition to the above alkylene oxide derivatives, 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate More preferred are copolymers, degacryceryl (eicosanedioic acid/tetradecanedioic acid), bisethoxydiglycol cyclohexanedicarboxylate, 1,2-pentanediol, 1,2-hexanediol, or 1,2-octanediol,
In addition to the above alkylene oxide derivatives, 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer, bisethoxydiglycol cyclohexanedicarboxylate, 1,2-pentanediol, and 1,2-hexanediol are even more preferred. The above component (C-2) may be used alone or in any combination of two or more.

In the skin external composition of the present invention, the total content of component (C-2) is not particularly limited, and (
B) It is set as appropriate depending on the type of component, the type of other ingredients, etc., but from the viewpoint of significantly achieving the effects of the present invention, preferably 0.001% by mass or more, based on the total amount of the composition, More preferably, it is 0.005% by mass or more, still more preferably 0.01% by mass or more, even more preferably 0.05% by mass or more, and most preferably 0.1% by mass or more.
The total content of component (C-2) is preferably 20% by mass or less, more preferably 15% by mass or less, even more preferably 12% by mass or less, and even more preferably, It is 10% by weight or less, most preferably 8% by weight or less.
The total content of component (C-2) is preferably 0.001 to 20% by mass, more preferably 0.005 to 15% by mass, and even more preferably 0.01 to 12% by mass, based on the total amount of the composition. %
, even more preferably from 0.05 to 10% by weight, most preferably from 0.1 to 8% by weight.

In the skin external composition of the present invention, the ratio of the total content of component (C-2) to component (B) is not particularly limited, but the ratio of component (C-2) to 1 part by mass of component (B) is , preferably 0.01 to 50,000 parts by weight, more preferably 0.05 to 10,000 parts by weight, and even more preferably 0.1 to 5,000 parts by weight.

In the skin external composition of the present invention, the content of the alkylene oxide derivative alone relative to the total amount of the composition is not particularly limited as long as the effects of the present invention are achieved.
The content of the alkylene oxide derivative alone is preferably 0.00% based on the total amount of the composition.
01% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.5% by mass
That's all.
The content of the alkylene oxide derivative alone is preferably 15% based on the total amount of the composition.
It is at most 10% by mass, more preferably at most 10% by mass, even more preferably at most 8% by mass.
The content of the alkylene oxide derivative alone is preferably 0.00% based on the total amount of the composition.
01 to 15% by weight, more preferably 0.1 to 10% by weight, even more preferably 0.5 to 8% by weight, even more preferably 0.5 to 5% by weight.

In the skin external composition of the present invention, the content of decaglyceryl (eicosanedioic acid/tetradecanedioic acid) alone relative to the total amount of the composition is not particularly limited as long as the effects of the present invention are achieved.
The content of decaglyceryl (eicosandioic acid/tetradecanedioic acid) alone is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, and even more preferably, The content is 0.01% by mass or more, and even more preferably 0.05% by mass or more.
The content of decaglyceryl (eicosandioic acid/tetradecanedioic acid) alone is preferably 15% by mass or less, more preferably 10% by mass or less, still more preferably 8% by mass or less, based on the total amount of the composition. , even more preferably 5% by mass.
The content of decaglyceryl (eicosandioic acid/tetradecanedioic acid) alone is preferably 0.001 to 15% by mass, more preferably 0.005 to 10% by mass, and even more preferably is 0.01 to 8% by weight, even more preferably 0.05% by weight
~5% by mass.

In the skin external composition of the present invention, the content of bisethoxydiglycol cyclohexanedicarboxylate alone relative to the total amount of the composition is not particularly limited as long as the effects of the present invention are achieved.
The content of bisethoxydiglycol cyclohexanedicarboxylate alone is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, still more preferably 0.01% by mass, based on the total amount of the composition. % or more, even more preferably 0.05% by mass or more.

The content of bisethoxydiglycol cyclohexanedicarboxylate alone is preferably 15% by mass or less, more preferably 10% by mass or less, still more preferably 8% by mass or less, and even more preferably is 5% by mass.
The content of bisethoxydiglycol cyclohexanedicarboxylate alone is preferably 0.001 to 15% by mass, more preferably 0.005 to 10% by mass, and still more preferably 0.001 to 15% by mass, based on the total amount of the composition. 01-8% by weight, even more preferably 0.05% by weight
~5% by mass. The content of bisethoxydiglycol cyclohexanedicarboxylate alone is preferably 10% by mass or less, more preferably 8% by mass or less, still more preferably 5% by mass or less, based on the total amount of the composition.

The content of bisethoxydiglycol cyclohexanedicarboxylate alone is preferably 0.001 to 10% by mass, more preferably 0.005 to 8% by mass, and still more preferably 0.001 to 10% by mass, based on the total amount of the composition. 0.01 to 5% by weight, even more preferably 0.05 to 3% by weight.

In the skin external composition of the present invention, the content of the 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer based on the total amount of the composition is not particularly limited as long as the effects of the present invention are achieved.
The content of the 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer alone is preferably 0.0001% by mass or more, more preferably 0.001% by mass or more, even more preferably is 0.005% by mass or more, even more preferably 0.01% by mass or more.
The content of the 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer is preferably 2% by mass or less, more preferably 1% by mass or less, and still more preferably 0. 5% by mass or less, even more preferably 0.2% by mass
It is as follows.
The content of the 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer is preferably 0.0001 to 2% by mass, more preferably 0.001 to 1% by mass, based on the total amount of the composition. More preferably, it is 0.005 to 0.5% by weight, even more preferably 0.01% to 0.2% by weight.

In the skin external composition of the present invention, the content of the alkanediol having 5 to 10 carbon atoms alone relative to the total amount of the composition is not particularly limited as long as the effects of the present invention are achieved.
The content of the alkanediol having 5 to 10 carbon atoms alone is preferably 0.0001% by mass or more, more preferably 0.001% by mass or more, even more preferably 0.01% by mass, based on the total amount of the composition. It is at least 0.1% by mass, even more preferably at least 0.1% by mass.
The content of the alkanediol having 5 to 10 carbon atoms alone is preferably 10% by mass or less, more preferably 7% by mass or less, still more preferably 5% by mass or less, and even more preferably, based on the total amount of the composition. Preferably, it is 3% by mass or less.
The content of the alkanediol having 5 to 10 carbon atoms alone is preferably 0.0001 to 10% by mass, more preferably 0.001 to 7% by mass, even more preferably 0. .01 to 5% by weight, even more preferably 0.1 to 3% by weight.

In the skin external composition of the present invention, the (C) component may contain a combination of any one or more of the (C-1) components and any one or more of the (C-2) components. preferable.

The external skin composition of the present invention may contain a combination of any one or more of the (C-1) components and any one or more of the (C-2) components as the (C) component. preferable.

Such a combination includes (C-1) component ascorbic acid, tranexamic acid,
Citric acid, salicylic acid, lactic acid, gluconic acid, kojic acid, tartaric acid, succinic acid, phytic acid,
Glycolic acid, sodium ascorbate, sodium salicylate, sodium lactate, sodium citrate, disodium citrate, trisodium citrate, sodium succinate, disodium succinate, sodium pyrrolidone carboxylate, sodium glutamate,
Dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside, sodium stearoylglutamate, Polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether, polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene glyceryl, which are sodium lauroyl glutamate and sodium lysine dilauroyl glutamate (C-2) components. Ether, polyoxybutylene polyoxyethylene polyoxypropylene alkyl glucoside, polyoxyethylene methyl glucoside, polyoxypropylene methyl glucoside, polyoxypropylene diglyceryl ether, polyoxyethylene diglyceryl ether, polyoxypropylene alkyl ether, polyoxyethylene poly Oxypropylene decyl tetradecyl ether, polyoxyethylene polyoxypropylene butyl ether, 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer liquid, polymethacryloyloxyethylphosphorylcholine, (eicosanedioic acid/tetradecanedioic acid) polyglyceryl-10, cyclohexane dicarbonate It is preferable to combine one or more selected from the group consisting of bisethoxydiglycol acid, diethoxyethyl succinate, and diethylhexyl succinate,
(C-1) Ingredients ascorbic acid, tranexamic acid, citric acid, lactic acid, salicylic acid, gluconic acid, phytic acid, tartaric acid, succinic acid, disodium succinate, sodium ascorbic acid phosphate, magnesium ascorbic acid phosphate, 2-O-ethyl ascorbic acid, 3-O-ethyl ascorbic acid, ascorbic acid-2-glucoside and (C-2) component polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether, polyoxyethylene polyoxy Propylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene alkyl glucoside, polyoxyethylene methyl glucoside, polyoxypropylene methyl glucoside, polyoxyethylene polyoxypropylene decyl tetradecyl ether , polyoxyethylene polyoxypropylene butyl ether, 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer liquid, (eicosanedioic acid/tetradecanedioic acid) polyglyceryl-10,
It is more preferable to combine one or more selected from the group consisting of bisethoxydiglycol cyclohexanedicarboxylate, diethoxyethyl succinate, and diethylhexyl succinate.

In particular, when component (C-2) is added to the skin external composition of the present invention, it has a good feeling of use (penetrating feeling, moisturizing property, etc.) while sufficiently maintaining the antiseptic effect, and also has nicotinic acid amide. It is possible to realize a formulation that combines various efficacies and good stability (precipitation).

[Other useful ingredients]
In addition to the (A) component, (B) component, and (C) component, the skin external composition of the present invention has other useful effects such as a UV absorber, a UV protectant, a whitening component, Anti-inflammatory ingredients, acidic mucopolysaccharides, etc. can be added. These components are not particularly limited as long as they can be used in the fields of pharmaceuticals, quasi-drugs, and cosmetics, and any components can be appropriately selected and used.

(UV absorber)
The UV absorber is not limited, but preferably includes a salicylic acid UV absorber, a cinnamic acid UV absorber, a benzoylmethane UV absorber, a benzoic acid ester derivative UV absorber, a triazine derivative UV absorber, and benzal. Examples include malonate derivative ultraviolet absorbers, octocrylene ultraviolet absorbers, imidazole sulfonic acid derivative ultraviolet absorbers, and benzophenone derivative ultraviolet absorbers.

In the present invention, examples of such UV absorbers include, but are not limited to, 2-ethylhexyl paramethoxycinnamate, 4-tert-butyl-4'-methoxydibenzoylmethane, 2-[4-(diethylamino)- 2-Hydroxybenzoyl]benzoic acid hexyl ester, dimethoxybenzylidene dioxoimidazolidine propionate 2-ethylhexyl ester, 2,2'-methylenebis[6-(2H-benzotriazol-2yl)-4-(1,1)
,3,3-tetramethylbutyl)phenol], 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,
3,5-triazine, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine, dimethicodiethylbenzalmalonate, 2-cyano-3,3- Diphenylprop-2-enoic acid 2-ethylhexyl ester, 2-phenylbenzimidazole-5-sulfonic acid are preferred, 2-ethylhexyl para-methoxycinnamate, 4-tert-butyl-4'-methoxydibenzoylmethane, 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoic acid hexyl ester, 2,4-bis-
[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4,6-tris[4-(2-ethylhexyl) oxycarbonyl)anilino]-1,3,5-triazine, 2-phenylbenzimidazole-5-sulfonic acid is more preferred, and 2-ethylhexyl para-methoxycinnamate, 2-[4-(diethylamino)-2- hydroxybenzoyl]benzoic acid hexyl ester, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4,6-tris[
Even more preferred is 4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine.

The ultraviolet absorber can be a commercially available product or can be synthesized.

Commercially available products include, but are not limited to, Uvinul MC80 (BASF
(manufactured by DSM Nutrition Japan), Parsol 1789 (manufactured by DSM Nutrition Japan), etc. can be used in appropriate combination.

The total content of ultraviolet absorbers based on the total amount of the skin external composition is preferably 1 to 20% by mass.
, more preferably 3 to 20% by weight, even more preferably 5 to 20% by weight, particularly more preferably 6 to 20% by weight, most preferably 7 to 15% by weight.

In the skin external composition of the present invention, the content ratio of the ultraviolet absorber to component (A) is not particularly limited, but is preferably 0.6 to 2 parts by mass of the total content of component (A). Parts by weight, more preferably 1 to 2 parts by weight, even more preferably 1.4 to 2 parts by weight.

(UV protection agent)
Examples of UV protection agents include inorganic compounds such as zinc oxide, titanium oxide, iron oxide, cerium oxide, zirconium oxide, titanium silicate, zinc silicate, anhydrous silicic acid, cerium silicate, and hydrated silicic acid; Inorganic compounds coated with inorganic powders such as hydrous silicic acid, aluminum hydroxide, mica, and talc, or composites with resin powders such as polyamide, polyethylene, polyester, polystyrene, and nylon, as well as silicone oil and fatty acid aluminum. Examples include those treated with salts, alkyl titanates, etc. Among these, inorganic compounds such as zinc oxide, titanium oxide, and iron oxide, and those obtained by coating these inorganic compounds with inorganic powders such as aluminum hydroxide, hydrous silicic acid, mica, and talc, and silicone oil are preferable. When blending an ultraviolet protection agent, its content can be appropriately selected in consideration of the feeling and effect on the skin, but for example, from 0.001 to 35% by mass, based on the total amount of the skin external composition of the present invention, Preferably 0.1-1
It is 0% by mass.

Further, in the present invention, although not limited to, the ultraviolet absorber and the ultraviolet protective agent may be composited, supported, or encapsulated by another component, and the combination thereof is not particularly limited.

(whitening ingredient)
The skin external composition of the present invention may contain whitening ingredients other than nicotinamide. For example, placenta, arbutin, rusinol, chamomilla ET, hydroquinone,
Tocopherol (α, β, δ, etc.), plant extracts (e.g., iris root extract, almond oil, aloe vera extract, acerola extract, age extract, scutellariae extract, hypericum extract, deadlock root extract, seaweed extract, cuckoo extract, chamomile) extract,
Peony extract, soybean extract, soybean extract, tea extract, sirloin extract, calendula, hamamelis, chinensis, adlay extract, hop extract, prune extract, licorice extract, oil-soluble licorice extract, meadowsweet extract, purple kibu extract, alpinia radish seed extract, Grave fruit extract, Izayoibara extract,
Lemon extract, kiwi extract, pine extract, neem leaf extract, artichoke extract,
Examples include horsetail extract, Japanese trumpet extract, evening primrose extract, evening primrose oil, bilberry leaf extract, Japanese sardine extract, salicaria extract, white willow extract, centella asiatica extract, and cornelian fruit extract. Among them, alpha tocopherol, delta tocopherol, beta tocopherol, iris root extract, aloe vera extract, acerola extract,
Scutellaria extract, Scutellaria extract, Hypericum extract, Hypericum extract, Seaweed extract, Cucumber extract, Chamomile extract, Peony extract, Soybean extract, Soybean extract, Tea extract, Shirocha extract, Calendula extract, Hamamelis extract, Coix extract, Coix extract, Prune extract, Licorice extract, oil-soluble licorice extract, Alpinia japonica seed extract, grape fruit extract, Izayo rosea extract, lemon extract, kiwi extract, artichoke extract, horsetail extract, Japanese trumpet extract, evening primrose extract, evening primrose oil, bilberry leaf extract, Japanese primrose extract, Salicorum extract , white willow extract, Centella asiatica extract, and cornelian fruit extract are preferred.

When the composition for external use on the skin of the present invention contains a whitening ingredient other than nicotinic acid amide as described above, the content thereof can be appropriately selected in consideration of the feeling of use and effect on the skin. With respect to the total amount of the composition, the content when using other than plant extracts is, for example, 0.
．． 01 to 5% by mass. When using a plant extract, the content is, for example, 0.00001 to 20% by mass, preferably 0.001 to 10% by mass, based on the total amount of the skin external composition in terms of extract such as extract. .

(Anti-inflammatory ingredient)
Anti-inflammatory ingredients include, for example, ingredients derived from plants (such as ingredients derived from comfrey, orensis, and Houtodyami), calamine, allantoin, zinc oxide, pyridoxine hydrochloride, tocopherol acetate, menthol, camphor, turpentine oil, Examples include ufenamate, bufexamac, ibuprofenpiconol, azulene and its derivatives (eg, guaiazulene, azulene, etc.), steroids and the like. When adding an anti-inflammatory component, the amount is, for example, 0.0003 to 10% by mass, preferably 0.0003 to 10% by mass, based on the total amount of the skin external composition of the present invention.
001 to 5% by mass.

(Acidic mucopolysaccharide)
Acidic mucopolysaccharides include hyaluronic acid, heparin-like substances, and the like.

Hyaluronic acid extracted from animal tissue or microorganisms generally has an average molecular weight of about 10.
It is said to have a molecular weight of more than 0,000,000 and is known to be extremely high molecular weight. In the present invention, such high-molecular hyaluronic acid may be used, or low-molecular-weight hyaluronic acid, hyaluronic acid oligosaccharides (tetrasaccharides, hexasaccharides, sugar, 8 sugars, etc.)
, unsaturated hyaluronic acid (having double bonds at the 4- and 5-positions of D-glucuronic acid) may be used.

Salts of hyaluronic acid or its derivatives are also not particularly limited as long as they are pharmacologically or physiologically acceptable. Examples include salts with metals. Preferably, as the salt of hyaluronic acid or its derivative, sodium salt, potassium salt,
Zinc salts are used.

Heparin-like substance is a general term for polysulfated mucopolysaccharides such as chondroitin polysulfate, and has an average of 0.5 to 5 molecules of sulfuric acid per monosaccharide molecule constituting the mucopolysaccharide, preferably an average of 0.6 to 3 molecules of sulfuric acid. It is preferable to have a group. More specifically, heparin-like substances include heparin, chondroitin sulfate D, chondroitin sulfate E, etc. called chondroitin polysulfate.

In the present invention, such acidic mucopolysaccharides include, but are not limited to, hyaluronic acid, low molecular weight hyaluronic acid, hyaluronic acid oligosaccharide (tetrasaccharide), acetylated hyaluronic acid, cationized hyaluronic acid, and hydrolyzed hyaluronic acid. Preferred are alkyl (C12-13) glyceryl, cross-linked hyaluronic acid, carboxymethyl hyaluronic acid, alkylene glycol hyaluronate, dimethyl silanol hyaluronate, heparin-like substances and/or salts thereof, and hyaluronic acid, low-molecular-weight hyaluronic acid, and acetylated hyaluronic acid. acid, hydroxypropyltrimonium hyaluronate, carboxymethyl hyaluronic acid, propylene glycol hyaluronate, sodium hyaluronate, zinc hyaluronate, low molecular weight zinc hyaluronate, acetylated sodium hyaluronate, sodium hyaluronate crosspolymer, and heparin-like substances. More preferred are sodium hyaluronate, zinc hyaluronate, low molecular weight zinc hyaluronate, acetylated hyaluronic acid, hydroxypropyltrimonium hyaluronate, propylene glycol hyaluronate, sodium hyaluronate crosspolymer, and heparin-like substances.

The acidic mucopolysaccharide can be used as a commercially available product or synthesized.

These acidic mucopolysaccharides are
In the skin external composition of the present invention, preferably 0.0001 to 1
% by mass, more preferably 0.001 to 0.5% by mass.

[Other ingredients]
The skin external composition of the present invention can contain other components in addition to the (A) component, (B) component, and (C) component within a range that does not impair the effects of the present invention. Specific examples of other ingredients include cooling ingredients, moisturizing ingredients, antibacterial or sterilizing ingredients, vitamins, amino acids or derivatives thereof, cell activating ingredients, anti-aging ingredients, blood circulation promoting ingredients, keratin softening ingredients, astringent ingredients, Examples include anti-glycation components, peptides or derivatives thereof.

Examples of cooling ingredients include camphor, menthol (for example, l-menthol, dl-
menthol, menthyl glyceryl ether, menthyl lactate, menthyl 3-hydroxybutyrate, menthoxypropanediol, menthyl succinate, etc.), monoterpenes such as borneol, eugenol, cineol, thymol, bisabolol, α-pinene, or limonene, etc. sesquiterpenes, diterpenes, eucalyptus oil, peppermint oil, clove oil, cinnamon oil, peppermint oil, mint oil, tea tree oil, chamomile oil, rosemary oil, lemon oil,
Examples include essential oils such as orange oil, thyme oil, sage oil, and clove oil.

Moisturizing ingredients include, for example, sodium hyaluronate, heparin-like substances, sodium chondroitin sulfate, collagen, elastin, keratin, chitin, and high molecular compounds or their hydrolysates such as chitosan; amino acids such as glycine and arginine; urea. natural moisturizing factors such as , and; lipids such as ceramides, and phospholipids; trimethylglycine (
Betaine); hydroxyethyl urea; acrylic acid/acrylamide/dimethyldiallylammonium chloride copolymer; and adlay seed extract, mugwort leaf extract, chamomile extract, hamamelis extract, birch sap, Salicornia extract, lilac extract, tea extract, lavender oil and plant extracts such as perilla extract; and animal extracts such as placenta extract.

Antibacterial or bactericidal ingredients include, for example, chlorhexidine, benzalkonium chloride, acrinol, sulfur, resorcinol, ethanol, benzethonium chloride, adapalene, benzoyl peroxide, clindamycin, cresol, gluconic acid and its derivatives, povidone iodine. , potassium iodide, iodine, triclocarban, triclosan, photosensor No. 101, photosensor 201
phenoxyethanol, alkyldiaminoglycine hydrochloride, chlorhexidine gluconate, zinc paraphenolsulfonate, picrotonolamine, and miconazole.

Examples of vitamins include retinol derivatives (retinol, retinol acetate, retinol palmitate, etc.), vitamin A such as tocopheryl retinoate; tocopherol,
Vitamin E such as tocopherol acetate; Vitamin B2 such as riboflavin; Nicotinic acids other than nicotinamide; Vitamin D; vitamin K, γ-oryzanol, vitamin B
Type 1; vitamin B6 types such as pyridoxine hydrochloride; vitamin B12 types; folic acids; pantothenic acids such as panthenol; biotin; and vitamin-like acting factors such as carnitine and pyrroloquinoline quinone.

Examples of amino acids or derivatives thereof include betaine (trimethylglycine), proline, hydroxyproline, arginine, lysine, serine, glycine, alanine, phenylalanine, β-alanine, threonine, glutamine, asparagine, aspartic acid, cysteine, cystine, and methionine. , leucine, isoleucine, valine, histidine, taurine, γ-aminobutyric acid, γ-amino-β-hydroxybutyric acid, carnitine, carnosine, and creatine.

Cell activating ingredients include, for example, vitamins (retinol, thiamine, riboflavin, pyridoxine hydrochloride, pyrroloquinoline quinone pantothenate, etc.); tannins, flavonoids, saponins, allantoin, placenta, proteoglycans, photosensitizer No. 301, plant extracts ( For example, soybean, bilberry, lemongrass, aloe vera, chlorella, cypress,
Extracts of sagebrush, chamomile, dokudami, hops, carrots, etc.); royal jelly,
Royal jelly extract; examples include whey, yogurt extract, whey-derived extracts such as hydrolyzed milk protein, and yeast extract. Anti-aging ingredients include, for example, hydrolyzed soy protein, retinoids (retinol, retinoic acid, retinal, etc.), astaxanthin, coenzyme Q10, pangamic acid, ursolic acid, turmeric extract, sphingosine derivatives, silicon, silicic acid, N-methyl- L-serine, mevalonolactone, peptides (caprooyl tetrapeptide-3, oligopeptide-24, etc.), plant extracts (e.g., artichoke, bramble, seaweed, bilberry, birch, plantain, Japanese apricot, Scutellaria japonica, Hypericum perforatum, comfrey) , neem, wild rose, extracts of Japanese apricot, Japanese apricot, Botanpi, etc.). Among them, as cell activation ingredients and/or anti-aging ingredients, hydrolyzed soy protein, retinol, retinol acetate, retinol palmitate, caprooyl tetrapeptide-3, oligopeptide-24, artichoke leaf extract, seaweed extract, bilberry leaf extract. , comfrey leaf extract, neem leaf extract,
Himefuro extract is preferred.

Blood circulation promoting ingredients include, for example, plants (such as Panax ginseng, Ashitaba, arnica, ginkgo biloba, fennel, chiliflower, Dutch oak, chamomile, Roman chamomile, carrot, gentian, burdock, rice, hawthorn, shiitake, hawthorn, and juniper). , Chinese cabbage, Japanese cabbage, thyme, clove, chimpi, Japanese apricot, tonin, spruce, carrot, garlic, butcher bloom, grape, button, horse chestnut, melissa, yuzu, yellowtail, rosemary, rosehip, chimpi, Angelica, spruce, peach, apricot,
Ingredients derived from walnuts, corn); examples include dl-α-tocopherol acetate, tocopherol nicotinate, glucosylhesperidin, hesperidin, and glucosylhesperidin.

Examples of keratin softening ingredients include lanolin, urea, and sulfur.

Examples of astringent ingredients include zinc paraphenolsulfonate, zinc oxide, menthol,
and ethanol.

Examples of anti-glycation components include Buddleja axillaris leaf extract, plum fruit extract, edelweiss extract, ginkgo biloba extract, cherry leaf extract, pomegranate extract, plantain extract, hawthorn extract, peony extract, dokudami extract, bilberry leaf extract, Plant extracts such as green tea extract, black tea extract, horse chestnut extract, Roman chamomile extract, mugwort extract, evening primrose oil, amla fruit, fruit juice or their extracts, L-arginine, L-lysine, hydrolyzed casein, hydrolysable tannin , carnosine, etc.

Examples of peptides or derivatives thereof include keratinolytic peptides, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, succinylated atelocollagen,
Gelatin, elastin, elastin-degraded peptide, collagen-degraded peptide, hydrolyzed collagen, hydroxypropylammonium chloride hydrolyzed collagen, elastin-degraded peptide, conchiolin-degraded peptide, hydrolyzed conchiolin, silk proteolytic peptide,
Hydrolyzed silk, lauroyl hydrolyzed silk sodium, soybean proteolytic peptide, hydrolyzed soybean protein, wheat protein, wheat proteolytic peptide, hydrolyzed wheat protein, caseinolytic peptide, acylated peptide (palmitoyl oligopeptide, palmitoyl pentapeptide, palmitoyl) tetrapeptide, etc.).

Other components can be used alone or in combination of two or more. Furthermore, the ingredients are not limited to these, and known ingredients that are incorporated into external skin preparations such as cosmetics and pharmaceuticals can be used as appropriate.

[Base or carrier]
The skin external composition of the present invention may contain, in addition to the above-mentioned components (A), (B), and (C), as long as the effects of the present invention are not impeded from the viewpoint of improving the feeling of use and stability. It may also contain a base or carrier. Examples of bases or carriers include, but are not limited to, polyethylene glycol; glycol ether; lower alcohols such as ethanol and isopropanol; oil; surfactants; thickeners; Known ingredients that are included in external skin preparations, such as, can be used.

In the skin external composition of the present invention, an oil that functions as a base or carrier can also be used. Examples of such oils include hydrocarbon oils, ester oils, fats and oils, silicones, and waxes. Specifically, hydrocarbons such as liquid paraffin, liquid isoparaffin, squalane, vaseline, gelled hydrocarbons, and α-olefin oligomers; dimethicone, crosslinked methylpolysiloxane, highly polymerized methylpolysiloxane, phenyl-modified silicone, cyclic silicone, Silicones such as polyether-modified silicones; higher alcohols; higher fatty acids; isopropyl myristate, octyldodecyl myristate, isopropyl palmitate, cetyl palmitate, isononyl isononanoate, diisopropyl adipate, decyl oleate, isodecyl oleate, dimethyl octane hexyldecyl acid,
Diisopropyl sebacate, di-2-ethylhexyl sebacate, 2-hexyldecyl myristate, 2-hexyldecyl palmitate, diisopropyl adipate, isotridecyl isononanoate, cetyl lactate, isostearyl isostearate, cholesteryl 12-hydroxystearate, stearin Cholesteryl acid, cholesteryl oleate, phytosteryl macadamia nut fatty acid, phytosteryl oleate, dextrin palmitate, inulin stearate, hydrogenated jojoba oil, ethylene glycol di-2-ethylhexylate, dipentaerythritol fatty acid ester, neopentyl glycol dicaprate, trimellito tri2-ethylhexyl acid, tridecyl trimellitate, trimethylolpropane tri-2-ethylhexylate, trimethylolpropane triisostearate,
Pentaerythritol tetra-2-ethylhexanoate, glycerin tri-2-ethylhexanoate, trimethylolpropane triisostearate, tri(caprylic acid/capric acid) glyceryl, tri(caprylic acid/capric acid/myristic acid/stearic acid) Glyceryl, oleyl oleate, di(phytosteryl/octyldodecyl) lauroylglutamate, di(octyldodecyl/phytosteryl/behenyl) lauroylglutamate, triethyl citrate, dimer dilinoleic acid (phytosteryl/isostearyl/cetyl/
Esters such as stearyl/behenyl), dilinoleyl dimer dilinoleate, dipentaerythrityl tripolyhydroxystearate, glyceryl tri(behenic acid/isostearic acid/eicosandioate); waxes such as jojoba oil and miur wax; avocado oil, Macadamia nut oil, kukui nut oil, hazelnut oil, corn oil, olive oil, safflower oil, kyonin oil, cinnamon oil, jojoba oil, grape seed oil, sunflower oil, almond oil, shea butter, sasanquat oil, rapeseed oil, sesame oil, cacao butter , coconut oil, hydrogenated coconut oil, palm oil, palm kernel oil, Japanese oak kernel oil, Japanese oak, wheat germ oil, rice germ oil, rice bran oil, cottonseed oil,
Examples include oils and fats such as soybean oil, peanut oil, tea seed oil, evening primrose oil, and shea butter.

In the skin external composition of the present invention, a surfactant can also be used which functions as a base or carrier. Such bases or carriers include, for example, sorbitan fatty acid esters such as sorbitan stearate, sorbitan sesquioleate, sorbitan oleate, sorbitan isostearate, sorbitan laurate, and olive oil fatty acid sorbitan; polyoxyethylene monolaurate (20 ) Sorbitan, polyoxyethylene monolaurate (
80) Sorbitan, polyoxyethylene monostearate (20) Sorbitan, polyoxyethylene monooleate (20) Sorbitan, polyoxyethylene isostearate (
20) Polyoxyethylene sorbitan fatty acid esters such as sorbitan; glycerin fatty acid esters such as glycerin monooleate, glycerin monostearate, and glycerin monomyristate; glycerin alkyl ethers such as monoisostearyl glyceryl ether and monomyristyl glyceryl ether; diglyceryl Polyglycerin fatty acid esters such as monostearate, decaglyceryl decastearate, decaglyceryl decaisostearate, diglyceryl diisostearate; propylene glycol fatty acid esters such as propylene glycol monostearate; polyethylene glycol monostearate, etc. Polyethylene glycol fatty acid esters; hydrogenated castor oil derivatives such as polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene hydrogenated castor oil 80; polyoxyethylene monococonut oil Polyoxyethylene glycerin fatty acid esters such as fatty acid glyceryl; polyoxyethylene sterols and hydrogenated sterols such as polyoxyethylene phytosterol, polyoxyethylene phytostanol, and polyoxyethylene cholestanol; sucrose fatty acid esters; ether carboxylates, alkyl phosphorus Acid ester salts, N-acylamino acid salts such as sodium cocoylglycine, acylated taurates; Amines such as stearylamine and oleylamine; Polyoxyethylene/methylpolysiloxane copolymer, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, PEG -9 Silicone surfactants such as polydimethylsiloxyethyl dimethicone, or naturally derived surfactants such as lecithin, hydrogenated lecithin, saponin, surfactin sodium, cholesterol, and bile acids, etc., but are not limited to these. .

Examples of thickeners include guar gum, locust bean gum, carrageenan, xanthan gum, sclerotium gum, xanthan gum, gellan gum, dextran, pectin, pullulan, agar, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, alkyl acrylate and methacrylate. Copolymer, (hydroxyethyl acrylate/
(Na acryloyl dimethyl taurine) copolymer, (Na acrylate/Na acryloyl dimethyl taurine) copolymer, polyacrylic acid amide, polyethylene glycol, alginic acid, sodium alginate, propylene glycol alginate ester, macrogol, sodium chondroitin sulfate, and hydroxyethyl cellulose. Examples include cellulose thickeners (hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydrophobized hydroxypropyl methyl cellulose, carboxymethyl cellulose, etc.).

One type of base or carrier can be used alone or two or more types can be used in combination.

[Additive]
The skin external composition of the present invention may include known additives added to pharmaceuticals, quasi-drugs, or cosmetics, such as antioxidants, pH adjusters, and stabilizers, to the extent that the effects of the present invention are not impaired. agent,
Colorants, perfumes, powder and/or pearlescent agents, irritation reducers, etc. can be added.

Examples of the antioxidant include dibutylhydroxytoluene, butylhydroxyanisole, sodium sulfite, tocopherol, tocopherol derivatives, and L-cysteine hydrochloride.

Examples of the pH adjuster include inorganic acids and organic bases.

Examples of the stabilizer include sodium polyacrylate, dibutylhydroxytoluene, and butylhydroxyanisole. Examples of irritation reducing agents include licorice extract and sodium alginate.

Examples of the coloring agent include pigment-grade titanium oxide, zinc oxide, iron oxide, organic pigments, talc, sericite, mica, synthetic mica, chromium oxide, and gunjo.

In addition, powders may be added to improve the feel or add makeup effects, such as boron nitride, silica, alumina, aluminum hydroxide, metal soap, silicone powder, polymethyl methacrylate, etc. etc.

One kind of additive can be used alone or two or more kinds can be used in combination. Furthermore, the ingredients are not limited to these, and known ingredients that are incorporated into external skin preparations such as cosmetics and pharmaceuticals can be used as appropriate.

[pH]
The composition for external use on the skin of the present invention should normally have a liquid pH of 2.0 to 9.0, but from the viewpoint of low irritation to the skin and mucous membranes and good feeling on the skin, it is preferably pH 3.
．． 0 to 8.5, more preferably pH 4.0 to 8.0, even more preferably pH 4.5 to 8.5.
7.5, even more preferably pH 5.0 to 7.5.

[Method for producing skin external composition]
The method for producing the skin external composition of the present invention is not particularly limited, and in addition to the above components (A) to (C),
The above-mentioned other useful ingredients, other ingredients, bases/carriers, additives, etc., as appropriate,
It can be manufactured by selecting, blending, and emulsifying according to a conventional method.

[Properties/Formulation]
The properties of the skin external composition of the present invention are not particularly limited, and may be liquid, fluid, or semi-solid. In addition, formulation forms include, for example, solutions, suspensions, emulsions, creams,
It can be made into formulations such as emulsions, ointments, gels, liniments, lotions, aerosols, sheets made of nonwoven fabric impregnated with medicinal solutions, and sticks. Among these, emulsions, creams, emulsions, ointments, gels, lotions, sheets, and sticks are preferred, and creams, emulsions, gels, lotions, and sheets are particularly preferred. In addition, when it contains an oily base and an aqueous base like an emulsion, cream, or ointment, it may be a W/O type or an O/W type, but the feeling of use of the skin external composition of the present invention ( O/W type is more preferable from the viewpoint of stickiness, spreadability, moist feeling, freshness, penetration feeling, etc.).

[Use applications]
Specifically, when used as an external composition for quasi-drugs or cosmetics, for example,
Basic cosmetics such as lotions, emulsions, gels, creams, serums, sunscreen cosmetics, packs, masks, all-in-one gels, hand creams, body lotions, wipes, and body creams; as well as facial cleansers, hand soaps, Cleaning cosmetics such as makeup removers, body shampoos, shampoos, conditioners, and treatments; face makeup cosmetics such as BB creams, foundations, and makeup bases; lip cosmetics such as lip balms, lip liners, and lip gels; hair rinses, hair treatments,
Examples include hair cosmetics such as hair conditioners, hair gels, hair mousses, hair mist, hair lotions, and styling agents. Among these, external compositions for skin are particularly preferred. That is, the external composition of the present invention can be used as a skin external composition for pharmaceuticals, quasi-drugs, or cosmetics. The formulation form of the skin external composition is the same as that of the external skin composition of the present invention. In addition, usable bases or carriers, additives, and active ingredients, as well as preferred ones thereof, are the same as in the case of the external composition of the present invention.

[container]
The skin external composition of the present invention can be used by being stored in a container of an appropriately selected shape and material depending on the purpose and use. Specific containers include, for example, spray type, bottle type, tube type, jar type, dropper type, dispenser type,
Examples include stick types, pouch bags, and chia packs. The skin external composition of the present invention can be used in a preferred state from the viewpoint of ease of removal from the container, and therefore can increase the degree of freedom in designing formulations containing a high concentration of nicotinic acid amide. That is,
Even high-concentration nicotinamide-containing formulations can be easily used in a wide variety of containers such as jars and sticks, as well as sprays, bottles, tubes, and dispensers.

Examples of the material of the container include polyethylene terephthalate, polypropylene, polyethylene (HDPE, LDPE, LLDPE, etc.), ABS resin, ethylene vinyl alcohol resin, polystyrene, glass, and metal (aluminum, etc.). In addition, these materials are treated with various coatings, combined by mixing, or laminated, taking into account strength, flexibility, weather resistance, or stability of ingredients. , can be used as a container material. Among them, polypropylene, polyethylene (HDPE, LD
It is preferable to use PE, LLDPE, etc.), ethylene vinyl alcohol resin, and metal (aluminum, etc.).

[How to use, etc.]
The skin external composition of the present invention can be suitably used for the purposes of promoting blood circulation, anti-inflammation, and promoting ceramide synthesis in anticipation of the physiological activity of nicotinamide. Furthermore, it can be expected to have whitening, anti-wrinkle, and anti-aging effects, and is useful as a multifunctional preparation, including as a whitening agent and sunscreen. The skin external composition of the present invention can be divided into once to several times per day depending on the purpose etc.
It can be used in a known or customary manner and dose.

[Precipitation suppression method]
In another embodiment, the present invention can also provide a method for inhibiting precipitation of a skin external composition containing (A) nicotinic acid amide. Precipitation of the composition for external use on skin is achieved by making the composition for external use on skin containing (A) nicotinic acid amide; (B) preservative; and (C) organic acid, organic acid salt, or amphipathic compound. can do.

As used herein, "precipitation" refers to, for example, a phenomenon in which components appear as solids (e.g., solid precipitates, needle-like crystals, fluffy fluff, etc.), regardless of the form of the skin external composition of the present invention. substance, etc.) There may be visible deposits. Or, for precipitation or solution transparency that is difficult to detect visually, use a turbidity meter and ultraviolet-visible-infrared spectrophotometer (model V-7).
70, manufactured by JASCO Corporation). For example, when the skin external composition of the present invention is prepared as an aqueous composition, it is preferably colorless and transparent;
It may precipitate over time. Precipitation suppression also includes preventing, retarding, and reducing such precipitation.

Next, the present invention will be specifically explained with reference to Examples, but the present invention is not limited to the following Examples.

The components used in the examples are as follows. The numerical values in each table are the contents of the components themselves listed in the component names.

Polyoxypropylene methyl glucoside (10P.O.): Macbiobride MG-1
0P (manufactured by NOF Corporation)
Polyoxyethylene polyoxypropylene butyl ether (17E.O.) (17P.
O. ): UNILUBE 50MB-26 (manufactured by NOF Corporation)
Polyoxyethylene polyoxypropylene glyceryl ether (24E.O.) (24
P. O. ): UNILUBE 50TG-32 (manufactured by NOF Corporation)
Polyoxyethylene polyoxypropylene butyl ether (37E.O.) (38P.O
．． ): UNILUBE 50MB-168 (manufactured by NOF Corporation)
Polyoxybutylene polyoxyethylene polyoxypropylene methyl glucoside: Wilbride MG2070 (manufactured by NOF Corporation)
Polyoxypropylene diglyceryl ether (14P.O.): SY-DP14 (manufactured by Sakamoto Pharmaceutical Co., Ltd.)
Polyoxypropylene diglyceryl ether (9P.O.): SY-DP9 (manufactured by Sakamoto Pharmaceutical Co., Ltd.)
2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer: L
ipidure-PMB (BG) (manufactured by NOF Corporation)
Polyoxypropylene sorbitol (25P.O.): Uniol HS-1600D (manufactured by NOF Corporation).

[Low temperature storage test]
Prepare the compositions shown in Tables 1 to 7 using a conventional method, and add 20 mL of each sample to a 20 mL glass bottle.
Filled. These compositions were stored for one week in a constant temperature bath at 4° C., and the presence or absence of precipitation of crystalline substances was visually confirmed.

The results are also shown in Tables 1 to 7. All numerical values in the table are mass %.

As shown in Tables 1 to 7, in the comparative examples, when component (B) a preservative and (C) an organic acid, an organic acid salt, an organic acid derivative, or an amphipathic component were combined, precipitation occurred. A problem was discovered that was occurring. On the other hand, in Examples, it was found that when (A) nicotinic acid amide was further contained, precipitation over time was suppressed. In particular, as shown in Table 7, (C
A similar precipitation-suppressing effect was observed when component -1) tranexamic acid and component (C-2) 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer were added.

Furthermore, the compositions of the Examples shown in Tables 1 to 7 had excellent usability.

[Formulation example]
External skin compositions of the present invention were prepared based on the formulations shown in Tables 8 to 28 below. The numerical values in the table mean mass %.

In any of the formulation examples, a composition for external use on the skin that does not cause precipitation over time and has a good feel when used is obtained.

Claims (1)

(A) Nicotinamide (niacinamide) 3-10% by mass;
(B) a preservative; and (C) 1 to 2% by mass of one or more selected from the group consisting of tranexamic acid and its salts;
Contains
Optionally, as an amphipathic compound, 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer (polyquaternium-51), polymethacryloyloxyethylphosphorylcholine, bisethoxydiglycol cyclohexanedicarboxylate, (eicosanedioic acid/tetradecanedioic acid) ) Polyglyceryl-10, polyoxyethylene polyoxypropylene butyl ether, polyoxyethylene polyoxypropylene decyl tetradecyl ether, polyoxyethylene glycerin, polyoxyethylene polyoxypropylene glyceryl ether, polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether, May contain one or more selected from the group consisting of polyoxyethylene methyl glucoside, polyoxypropylene methyl glucoside, polyoxybutylene polyoxyethylene polyoxypropylene methyl glucoside, and polyoxyethylene polyoxypropylene glycol. Composition for external use on the skin.